Dendritic cell vaccines in tumor immunotherapy by Wurzenberger, Cornelia
  
 
Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
Dendritic cell vaccines in tumor immunotherapy: 
Immune activation strategies with ligands for the  
Toll-like receptors 7 and 9 
 
 
 
 
 
Cornelia Wurzenberger 
aus München 
2008 
 
  
 
 
Erklärung 
Diese Dissertation wurde im Sinne von § 13 Abs. 4 der Promotionsordnung vom  
29. Januar 1998 von Herrn Professor Dr. Stefan Endres und Frau Dr. Dr. Carole  
Bourquin betreut und von Frau Professor Dr. Angelika M. Vollmar vor der Fakultät  
für Chemie und Pharmazie vertreten.  
 
 
 
 
 
 
 
Ehrenwörtliche Versicherung 
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
 
München, am 09.12.2008 
 
 
 
 
        Cornelia Wurzenberger 
 
 
 
 
 
 
 
Dissertation eingereicht am:  09.12.2008 
1. Gutachter:    Prof. Dr. Stefan Endres 
2. Gutachter:    Prof. Dr. Angelika M. Vollmar 
Mündliche Prüfung am:  21.01.2009 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Dedicated to my family 
 
  
 
INDEX 
1 SUMMARY......................................................................................................................1 
2 INTRODUCTION .............................................................................................................5 
2.1 Dendritic cells .........................................................................................................7 
2.1.1 Functions of dendritic cells.................................................................................7 
2.1.2 Dendritic cell subsets .........................................................................................9 
2.1.3 Isolation or generation of dendritic cells ........................................................... 10 
2.1.4 Dendritic cell vaccines ..................................................................................... 11 
2.2 Toll-like receptors ................................................................................................ 13 
2.2.1 The Toll-like receptors and their ligands .......................................................... 13 
2.2.2 Signaling pathways of Toll-like receptors ......................................................... 16 
2.3 Objectives ............................................................................................................. 18 
3 MATERIALS AND METHODS ...................................................................................... 19 
3.1 Materials ............................................................................................................... 21 
3.1.1 Technical equipment........................................................................................ 21 
3.1.2 Chemicals, reagents and buffers ..................................................................... 21 
3.1.3 Kits .................................................................................................................. 23 
3.1.4 Cell culture reagents and media ...................................................................... 23 
3.1.5 FACS antibodies and MHC class I pentamers ................................................. 25 
3.1.6 Software .......................................................................................................... 26 
3.2 Cell culture ........................................................................................................... 26 
3.2.1 General culture conditions ............................................................................... 26 
3.2.2 C26 colon carcinoma cell line .......................................................................... 26 
3.2.3 Dendritic cells .................................................................................................. 27 
3.2.3.1 Generation of bone-marrow-derived dendritic cells ...................................... 27 
3.2.3.2 Antigen loading of dendritic cells.................................................................. 29 
3.2.3.3 In vitro activation of dendritic cells ............................................................... 29 
3.2.4 Isolation of DC and T-cell subtypes by magnetic cell separation (MACS) ........ 29 
3.2.5 Assessment of T-cell responses in vitro ........................................................... 30 
3.2.6 Analysis of DC-induced suppression of regulatory T-cell function .................... 31 
3.2.7 Transwell migration assays.............................................................................. 31 
3.3 Immunological methods ...................................................................................... 32 
3.3.1 Enzyme-linked immunosorbent assay (ELISA) ................................................ 32 
3.3.1.1 Cytokine ELISA ........................................................................................... 32 
 3.3.1.2 Measurement of immunoglobulin concentrations in mouse sera .................. 32 
3.3.2 Flow cytometry ................................................................................................ 33 
3.3.2.1 Analysis of surface molecule expression ..................................................... 33 
3.3.2.2 MHC pentamer staining ............................................................................... 34 
3.3.2.3 CFSE staining .............................................................................................. 34 
3.4 Animal experimentation ....................................................................................... 34 
3.4.1 Animals............................................................................................................ 34 
3.4.2 Organ and single cell preparation .................................................................... 35 
3.4.2.1 Preparation of serum and isolation of blood cells ......................................... 35 
3.4.2.2 Spleen cell isolation ..................................................................................... 35 
3.4.2.3 Preparation of bone marrow cells ................................................................ 35 
3.4.2.4 Isolation of lymph node cells ........................................................................ 36 
3.4.3 Immunization of mice ....................................................................................... 36 
3.4.3.1 Dendritic cell immunizations ........................................................................ 36 
3.4.3.2 Detection of specific immune responses ...................................................... 36 
3.4.4 C26 tumor experiments ................................................................................... 37 
3.4.4.1 Tumor challenge .......................................................................................... 37 
3.4.4.2 Dendritic cell therapy ................................................................................... 37 
3.4.4.3 Rechallenge of mice with tumor cells ........................................................... 38 
3.4.5 Analysis of in vivo migration of dendritic cells .................................................. 38 
3.5 Statistical analysis ............................................................................................... 38 
3.6 Molecular biology methods ................................................................................. 39 
3.6.1 RNA isolation ................................................................................................... 39 
3.6.2 Analysis of gene expression profiles by microarray ......................................... 39 
3.6.2.1 Generation and hybridization of cRNA ......................................................... 40 
3.6.2.2 Data readout and analysis ........................................................................... 40 
4 RESULTS ..................................................................................................................... 41 
4.1 Kinetics of dendritic cell activation by TLR9 in tumor therapy ......................... 43 
4.1.1 Cytokine production ......................................................................................... 43 
4.1.2 Expression of costimulatory molecules ............................................................ 45 
4.1.3 Induction of T helper cell responses ................................................................ 47 
4.1.4 Initiation of cytotoxic T-cell responses ............................................................. 48 
4.1.5 Inhibition of regulatory T-cell function .............................................................. 51 
4.1.6 Migratory capacity of short-term activated dendritic cells ................................. 52 
4.1.7 In vivo migration to draining lymph nodes ........................................................ 54 
4.1.8 Immunization with short-term activated dendritic cells ..................................... 55 
  
 
4.1.9 Tumor therapy with short-term activated dendritic cells ................................... 58 
4.2 Distinctive features of TLR7 stimulation ............................................................ 61 
4.2.1 Kinetics of TLR7-induced cytokine production ................................................. 61 
4.2.2 Lack of IL-12p70 production in TLR7-activated dendritic cells ......................... 62 
4.2.3 The role of p38 MAPK for IL-12p70 inhibition .................................................. 64 
4.2.4 Influence of various cytokines on IL-12p70 secretion ....................................... 65 
4.2.5 Gene expression profiles of TLR7- versus TLR9-stimulated FL-mDC .............. 66 
4.2.6 Integrating data by pathway analysis ............................................................... 71 
5 DISCUSSION ................................................................................................................ 73 
5.1 Kinetics of dendritic cell activation in tumor therapy ........................................ 75 
5.1.1 Advantages of Flt3L-generated dendritic cells for immunotherapy ................... 75 
5.1.2 The difficult choice of the right stimulus ........................................................... 76 
5.1.3 The danger of “exhausting” dendritic cells ....................................................... 77 
5.1.4 Duration and combination: signal integration in dendritic cells ......................... 78 
5.1.5 The need to generate multifunctional dendritic cells ........................................ 80 
5.2 Pathways to IL-12 production: TLR7 versus TLR9 signaling ............................ 81 
5.2.1 IL-12 as a crucial regulator of immune responses ............................................ 81 
5.2.2 IL-10 – an anti-inflammatory cytokine exerting regulatory feedback ................. 82 
5.2.3 IFN-β: the pivotal molecule? ............................................................................ 83 
5.3 Conclusion and perspectives .............................................................................. 84 
6 REFERENCE LIST ....................................................................................................... 87 
7 APPENDICES ............................................................................................................. 101 
7.1 Abbreviations ..................................................................................................... 103 
7.2 Publications ........................................................................................................ 107 
7.2.1 Original publications ...................................................................................... 107 
7.2.2 Oral presentations ......................................................................................... 108 
7.2.3 Poster presentations ...................................................................................... 108 
7.3 Curriculum vitae ................................................................................................. 110 
7.4 Acknowledgements ............................................................................................ 111 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Summary 
Summary 
3 
 
The main function of dendritic cells (DC) is to process antigenic material and present it to 
other cells of the immune system. As such, they act as mediators between the innate and the 
adaptive arm of the immune system. Due to their substantial ability to elicit effective memory 
responses and to break immunological tolerance to tumors, DC-based vaccines have 
emerged as a promising strategy for the immunotherapy of cancer. In these vaccines, the 
maturation state of the DC is of crucial importance for the success of vaccination, but the 
most effective mode of maturation is still a matter of debate.  
 
In the first part of this work, short-term activation of DC with CpG oligonucleotides as Toll-like 
receptor 9 ligands was investigated as a novel strategy to achieve optimal DC maturation. 
The kinetics of DC maturation are a critical factor for the induction of efficient immune 
responses, as immature DC carry the risk of inducing tolerance whereas extensive 
stimulation may lead to DC unresponsiveness and exhaustion. Short activation of DC for as 
little as 4 hours (versus 24 to 48 hours) induced fully functional DC that rapidly secreted 
IL-12p70 and IFN-α, expressed high levels of costimulatory and MHC molecules and 
efficiently presented antigen to CD4 and CD8 T cells. Furthermore, short-term activated DC 
overcame immune suppression by regulatory T cells and acquired high migratory potential 
toward the chemokine CCL21 necessary for DC recruitment to lymph nodes. In vivo, 
vaccination with short-term activated DC induced a strong cytotoxic T-cell response and led 
to the eradication of tumors. Thus, short-term activation of DC generates fully functional DC 
for tumor immunotherapy. These results may guide the design of new protocols for DC 
generation in order to develop more efficient DC-based tumor vaccines. 
 
The second part of this study centers on a novel finding characterizing Toll-like receptor 7 
activation in a subpopulation of myeloid DC: in contrast to Toll-like receptor 9 ligands, Toll-
like receptor 7 agonists fail to elicit secretion of bioactive IL-12p70 in these DC. This 
inhibition is highly selective, because other proinflammatory cytokines are efficiently induced 
by Toll-like receptor 7 stimulation. As IL-12 is an important cytokine for the induction of 
antitumoral immune responses, the regulation of IL-12p70 production upon Toll-like 
receptor 7 stimulation was examined by inhibition of signal transduction, use of gene-
deficient mice, and a genome-wide expression analysis by microarray. Several genes were 
identified that modulate IL-12 production in myeloid DC. These results add to the 
understanding of Toll-like receptor 7 stimulation, which is a promising alternative for the 
maturation of human DC. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Introduction 
 
 
 
 
Introduction 
7 
2.1 Dendritic cells 
2.1.1 Functions of dendritic cells 
The immune system protects organisms from infection by pathogenic microorganisms. As a 
first line of defense, physical barriers prevent bacteria and viruses from entering the 
organism. If a pathogen breaches these barriers, the innate immune system constitutes a 
second layer of protection. It provides an immediate but non-specific response based on the 
recognition of conserved molecular patterns of microorganisms via pattern-recognition 
receptors. Innate immune responses are found in all plants and animals. Vertebrates have 
however acquired a third line of defense, the adaptive immune system, which is activated by 
the innate immune response. This immune response is “adapted” during an infection to 
improve the recognition of the pathogen. Adaptive immunity allows for a stronger immune 
response as well as the development of immunological memory that enables the rapid 
elimination of microorganisms upon reinfection. Both innate and adaptive immunity depend 
on the recognition of invading microorganisms as non-self. While the innate immune system 
recognizes conserved microbial structures, the adaptive immune response is antigen-
specific, meaning that it detects specific features of each pathogen. Dendritic cells, 
macrophages, granulocytes and natural killer cells represent the most important cells of the 
innate immune system, whereas T and B cells are responsible for adaptive immune 
responses.  
 
Antigen-presenting cells that process antigenic material and present it on their surface to 
other cells of the immune system act as mediator between the innate and the adaptive arm 
of the immune system. In peripheral lymphoid organs, there are three main types of antigen-
presenting cells that can activate T cells – dendritic cells, macrophages, and B cells. The 
most potent of these are dendritic cells (DC), which are present in small numbers in tissues 
that are in contact with the external environment. Most DC reside in the skin, where a 
specialized DC type, now called Langerhans cell, was first described by Paul Langerhans in 
the late 19th century (Langerhans, 1868), and the mucosa of the respiratory and the intestinal 
tract. Langerhans cells can also be found in an immature state in the blood. At certain stages 
of development they grow branched projections, the dendrites, that gave the cell its name 
(Figure 2.1). Although first described by Paul Langerhans, it was not until 1973 that the term 
"dendritic cells" was coined by Ralph M. Steinman and Zanvil A. Cohn (Steinman and Cohn, 
1973). In 2007, Steinman was awarded the Albert Lasker Medical Research Award for his 
discovery. 
Introduction 
8 
 
Figure 2.1: Immunofluorescence micrograph of a dendritic cell (from Alberts, 2008).  
The distinct long processes called dendrites, which give the cell its name, are most pronounced in 
mature DC. This cell has been labeled with a monoclonal antibody that recognizes a surface antigen. 
 
DC are derived from hematopoietic bone marrow progenitor cells. These progenitor cells 
initially transform into immature DC which constantly sample the surrounding environment for 
pathogens. DC use phagocytosis, endocytosis, pinocytosis, and specific receptors to capture 
microbial pathogens, dead or dying cells, immune complexes, and other antigens for immune 
presentation (Rossi and Young, 2005). Once they have come into contact with a presentable 
antigen, they mature and migrate to regional lymph nodes. Upon maturation, peptides 
derived from the captured antigens are presented by major histocompatibility complex (MHC) 
molecules at the cell surface. In the lymph nodes, the now-mature DC induce an immune 
response by activating T cells with receptors that recognize the foreign peptide – MHC 
complex on the DC surface. Antigen-presenting cells usually present antigens acquired from 
the extracellular environment on class II MHC complexes binding to T-cell receptors on CD4+ 
T helper cells, whereas class I MHC molecules bear peptides synthesized in the cytosol and 
activate CD8+ cytotoxic T cells. DC, however, are capable of cross-presenting exogenous 
antigens on class I MHC complexes, thus allowing the induction of a cytotoxic T-cell 
response to pathogens that do not infect DC (Groothuis and Neefjes, 2005).  
 
Although effector T cells are triggered when their antigen-specific receptors bind to 
peptide - MHC complexes, ligation of the T-cell receptor does not, on its own, stimulate naïve 
T cells to proliferate and differentiate into effector T cells. The antigen-specific clonal 
expansion of naïve T cells requires a second costimulatory signal, which must be delivered 
by the same antigen-presenting cell on which the T cell recognizes its antigen. The best-
characterized costimulatory molecules are the structurally related glycoproteins CD80 (B7.1) 
and CD86 (B7.2), whose expression on DC is upregulated upon maturation and which bind 
to CD28 on T cells. CD40 on the other hand provides a sustained or modifying co-stimulatory 
signal driving clonal expansion and differentiation of T cells by binding to CD40L on T cells. 
The effects of this receptor-ligand interaction are bidirectional, with both the T cell and the 
DC receiving activating signals (Janeway, 2005).  
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The requirement for the simultaneous delivery of antigen-specific and costimulatory signals 
in the activation of T cells means that only DC that migrate into lymphoid tissues after being 
activated by ingesting pathogens can initiate T-cell responses. This is important to prevent 
destructive immune responses to self tissues. Antigen binding in the absence of 
costimulation not only fails to activate T cells, it leads instead to the induction of anergic 
T cells, which are refractory to activation, or of regulatory T cells, which suppress immune 
responses (Hawiger et al., 2001; Steinman et al., 2003).  
 
DC are constantly in communication with other cells in the body. This communication can 
take the form of direct cell-to-cell contact based on the interaction of cell-surface proteins or 
occur at a distance via cytokines. One of the most important cytokines secreted by DC is 
IL-12, which activates natural killer cells and polarizes T helper cells towards a Th1 
phenotype. However, depending on the type of DC and the maturation signal the DC 
receives, the cytokines produced may vary.  
2.1.2 Dendritic cell subsets 
Since the initial description of DC by Steinman and Cohn, it has become evident that DC are 
heterogeneous and consist of many distinct DC subtypes. Although all DC are capable of 
antigen uptake, processing and presentation to naïve T cells, the DC subtypes differ in 
location, migratory pathways, detailed immunological function and dependence on infections 
or inflammatory stimuli for their generation. DC subtypes in the steady state, in the absence 
of infection, include type I interferon-producing plasmacytoid DC (pDC), migratory DC 
located in peripheral tissues such as Langerhans cells, and lymphoid tissue-resident myeloid 
DC (mDC), also called conventional DC (Shortman and Liu, 2002). The latter group can 
further be subdivided into CD8+ and CD8- mDC in mice, according to their expression of 
CD8α on the cell surface (Vremec et al., 2000). These two subsets differ in their immune 
functions, with only the CD8+ mDC being able to cross-present exogenous antigens on 
MHC I complexes (den Haan et al., 2000). Lymphoid tissue-resident DC collect and present 
antigens in a single lymphoid organ without migrating. In contrast, migratory DC are the 
classical “text-book” DC that act as sentinels in peripheral tissues and migrate to the lymph 
nodes through the lymphatics, bearing antigens from the periphery. DC can also be divided 
into conventional DC which already have a dendritic form and exhibit DC function in steady 
state, and precursors of DC (pre-DC), which require further development to acquire a 
dendritic form and full DC function (Shortman and Naik, 2007). Different pre-DC populations 
produce different subtypes of DC, and further development of DC often requires a microbial 
or inflammatory stimulus. In this model, pDC are an example of pre-DC. DC, like other blood 
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cells, derive from hematopoietic stem cells, and both common myeloid and common 
lymphoid progenitor cells have the ability to form pDC, CD8+ and CD8- mDC (Manz et al., 
2001; Wu et al., 2001).  
 
Plasmacytoid DC represent a rare but important cell type and are characterized by the 
production of high amounts of type I interferons in response to viruses. In 1958, Lennert and 
Remmele described the presence of cells with a plasma cell-like morphology located in what 
are now known to be the T-cell zones of human lymph nodes and spleen (Lennert and 
Remmele, 1958). More than 40 years later, in 1999, it was determined that natural interferon-
producing cells were identical to the plasmacytoid subset of DC (Cella et al., 1999; Siegal et 
al., 1999) and the description of human pDC was followed by descriptions of pDC in mice 
(Asselin-Paturel et al., 2001; Nakano et al., 2001). Immature pDC are present in the blood, 
bone marrow and secondary lymphoid organs and can be recruited to the skin, the 
cerebrospinal fluid, the gut and the lung under stimulatory conditions. Moreover, pDC are 
known to infiltrate many tumors. 
 
Interferon (IFN) was the earliest described cytokine and first discovered for its ability to 
“interfere” with viral replication (Isaacs and Lindenmann, 1957). Since then, we have learned 
that interferons are a large family of genes comprising at least three different major subtypes: 
the type I interferons which include the IFN-α family and IFN-β, -κ, and –ω, the single type II 
interferon, IFN-γ, and the IFN-λs, which are also known as IL-28 and IL-29 (Fitzgerald-
Bocarsly and Feng, 2007). Type I interferons are known to have a number of effects on 
different cells of the immune system: they act as a survival factor for pDC and can enhance 
the maturation of mDC, while also upregulating the cytokine and chemokine response in DC 
in an autocrine or paracrine manner (Fitzgerald-Bocarsly and Feng, 2007). They lead to the 
activation of natural killer cells and are able to induce the production of IFN-γ by CD4+ 
T cells, thus exerting a strong Th1-bias on T-cell differentiation (Brinkmann et al., 1993). 
IFN-α was also demonstrated to enhance the antibody response to soluble antigen (Le Bon 
et al., 2001). Thus, type I interferons are not only important mediators of anti-viral immunity 
but also provide a link between the innate and adaptive immune system as do the dendritic 
cells. 
2.1.3 Isolation or generation of dendritic cells 
In the peripheral blood of healthy individuals, DC represent a minor fraction of mononuclear 
cells (less than 1%). The capacity of DC to efficiently initiate and regulate lymphocyte-
mediated immunity has led to the study of DC as cellular vaccine adjuvants for 
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immunizations and for the immunotherapy of cancer (Schuler and Steinman, 1997). 
However, the feasibility of using DC in immunotherapy is limited by the small number of DC 
that can be isolated from peripheral blood. Therefore, the majority of applications currently 
rely on the in vitro generation of DC from precursor cells. In the field of DC biology, by far the 
most work has been carried out using mDC obtained by culturing peripheral blood 
monocytes or bone marrow cells in the presence of GM-CSF and IL-4. However, these cells 
do not show the same heterogeneity in phenotype and function as ex vivo DC, and the 
preferential expansion of only myeloid-related DC may not necessarily provide the 
appropriate signals that would result in the generation of optimal T-cell responses (Mortarini 
et al., 1997). In contrast, the hematopoietic growth factor fms-like tyrosine kinase 3 ligand 
(Flt3L) induces the proliferation and survival of hematopoietic progenitor and stem cells 
(Lyman and Jacobsen, 1998). The in vivo administration of Flt3L expands the number of both 
myeloid and plasmacytoid DC subsets in mice and men (Maraskovsky et al., 1996; 
Maraskovsky et al., 2000) and allows the isolation of large numbers of DC from blood that 
efficiently prime immune responses. This has also been shown in cancer patients, where 
Flt3L-expanded DC primed immune responses to cancer antigens (Davis et al., 2006). In a 
murine tumor model, the synergism of Flt3L-derived myeloid and plasmacytoid DC proved to 
be more effective in increasing the levels of antigen-specific cytotoxic T lymphocytes (CTL) 
and in inducing an enhanced antitumor response than immunizations with either DC subset 
alone (Lou et al., 2007). Culture of murine bone marrow cells with Flt3L was described to 
generate bona fide counterparts of splenic ex vivo DC subsets, those being plasmacytoid 
DC, CD8+ and CD8- myeloid DC (Naik et al., 2005). 
2.1.4 Dendritic cell vaccines 
Vaccination against infectious diseases by injecting antigens mixed with adjuvants targeted 
and activated DC in situ long before the existence of these cells was known. Although this 
approach is highly effective against viral and bacterial pathogens in a prophylactic setting, 
therapeutic vaccines against cancer have yet to meet expectations (Zhong et al., 2007). 
Factors that contribute to the limited efficacy of cancer vaccines are the preexisting cancer 
load (i.e. the tumor), the need to stimulate the cellular arm of the immune response to 
eradicate established tumors, and the fact that immune responses are suppressed in cancer 
patients (Gilboa, 2007). DC have emerged as a promising tool due to their ability to present 
tumor antigens and to initiate an immune response, induce memory cells and break 
immunological tolerance against the tumor. The most popular approach in tumor immunology 
is to immunize cancer patients with autologous, patient-derived DC loaded with tumor 
antigens ex vivo. Figure 2.2 shows an overview of current vaccine protocols, where DC are 
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mainly derived from monocytes or CD34+ precursor cells, cultured in the presence of various 
cytokine mixtures to produce immature DC, and loaded with antigen either before or 
following DC maturation. The clinical trials so far have provided valuable information on DC-
based therapy: it is safe and well tolerated with side effects generally limited to induration at 
the injection site and a mild fever. Furthermore, the importance of the quality of the DC was 
emphasized, especially with regard to their migratory capacity and their ability to induce 
potent T-cell responses (Tacken et al., 2007). Although conclusions from the first clinical 
trials were fairly optimistic due to the fact that the majority of patients developed T cell-
mediated antitumor immune responses, recent reviews, however, began to express 
skepticism regarding the clinical effectiveness of autologous tumor antigen-loaded DC 
(Zhong et al., 2007). Thus, all the steps depicted in Figure 2.2 are subject to optimizing 
strategies in order to influence the efficacy of DC-based tumor vaccines. Problems that 
remain to be solved despite extensive research on DC vaccination include the optimal DC 
subtype to be used, the most efficient antigen-loading and activation of DC, and the best 
route of DC administration. A list of published trials on DC-based cancer vaccines since the 
first clinical study in 1995 (Mukherji et al., 1995) has been made available on the Internet 
(http://www.mmri.mater.org.au/) and allows a comparison of strategies pursued so far. 
 
DC isolation / 
differentiation
Antigen pulsing Route of 
immunization
Activation
Monocytes or 
precursor cells
+ Pro-inflammatory 
mediators, chemokines, 
CD40L, TLR agonists
Subcutanous, 
intranodal, intra-
venous injection
+ Growth factors
+ RNA, peptides, 
proteins, or tumor 
lysates
 
Figure 2.2: DC-based vaccines using ex vivo loaded DC to induce immunity. 
Further research is needed to determine the optimal procedures for each step of the generation of DC 
vaccines, starting with the isolation or generation of DC, the optimal method to load DC with antigens, 
the most efficient maturationand activation stimulus, and the most efficient application of matured DC.  
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2.2 Toll-like receptors 
2.2.1 The Toll-like receptors and their ligands 
Toll-like receptors (TLRs) are of interest to immunologists because of their front-line role in 
the initiation of innate immunity against invading pathogens. They are evolutionarily 
conserved molecules that were originally described to stimulate the production of 
antimicrobial proteins in Drosophila melanogaster (Lemaitre et al., 1996). Mammalian TLRs 
are a family of membrane proteins that trigger innate immune responses through nuclear 
factor-κB (NF-κB)-dependent and IFN-regulatory factor (IRF)-dependent signaling pathways 
(Trinchieri and Sher, 2007). The TLR family members are pattern-recognition receptors that 
collectively recognize lipid, carbohydrate, peptide and nucleic-acid structures expressed by 
different groups of microorganisms. Some TLRs are found at the cell surface (TLR1, 2, 4, 5, 
and 6), while others are expressed on the membrane of endocytic vesicles (TLR3, 7, 8, 
and 9). Other groups of pattern-recognition receptors, such as the C-type lectin-like 
molecules on the cell surface and the cytosolic NLR (nucleotide-binding oligomerization 
domain-like receptors) and RIG-I-like helicases (retinoic-acid-inducible gene I), also 
participate in the binding and uptake of microbial components and can cooperate with the 
Toll-like receptors in the innate immune response to pathogens (Trinchieri and Sher, 2007).  
Figure 2.3 shows a schematic representation of the different Toll-like receptors and their 
main target transcription factors. 
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Figure 2.3: Overview of the Toll-like receptors and their main target transcription factors. 
The family of Toll-like receptors includes cell-surface receptors (TLR1, 2, 4, 5, 6, and 11) that 
recognize microbial proteins and lipids, and endosomal receptors (TLR3, 7, 8, and 9) which bind to 
nucleic acids. Both types induce the activation of the NF-κB signaling pathway and the production of 
type I interferons. This schematic overview shows only receptors and main target transcription factors 
that differ between the different Toll-like receptors.  
ds double-stranded, IFN interferon, IRF IFN-regulatory factor, LPS lipopolysaccharide, NF-κB nuclear 
factor-κB, ss single-stranded, TLR Toll-like receptor. 
 
After the characterization of TLR4 as the first mammalian TLR, 12 other structurally related 
proteins were identified to date and named Toll-like receptors, although not all of them are 
conserved between species. Functionally, a critical role of TLR4 in the recognition of 
lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, 
was initially characterized (Poltorak et al., 1998). Further research subsequently identified 
ligands for most of the other TLRs as shown in Table 2.1. Accumulating evidence points to 
the possibility of endogenous molecules acting as TLR agonists, which is now thought to 
have an important role in the regulation of inflammation, but might also be responsible for 
certain autoimmune disorders. While TLR1, 2, and 6 recognize ligands by forming 
heterodimers, the other TLRs appear to function as homodimers, although the exact 
mechanisms of recognition have not yet been determined. Species-specific TLRs include 
TLR8, which is thought to be non- functional in murine immune cells, TLR10, which has only 
been identified in humans, and TLRs 11 to 13, that probably exist only in mice.  
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Table 2.1: Toll-like receptors and their ligands (adapted from Ishii et al., 2006). 
TLR Exogenous ligands Origin Endogenous ligands 
TLR1 + TLR2 Triacetylated lipopeptides Bacteria N.D. 
TLR6 + TLR2 Diacetylated lipopeptides, Zymosan 
Bacteria, 
fungi N.D. 
TLR3 Double-stranded RNA Viruses mRNA 
TLR4 
LPS, 
Taxol, 
fusion protein 
Bacteria, 
plants, 
viruses 
HSP, fibrinogen, 
fibronectin 
TLR5 Flagellin Bacteria N.D. 
TLR7 (TLR8) 
Single-stranded RNA, 
Imidazoquinolines 
(Imiquimod, Resiquimod), 
Loxoribine (guanosine 
analog) 
Viruses, 
 
synthetic RNA 
TLR9 
CpG DNA 
 
Hemozoin 
Bacteria, viruses, 
synthetic, 
Plasmodia 
Chromatin immune 
complexes 
TLR10 N.D.  N.D. 
TLR11 
N.D. 
 
Profilin-like protein 
Uropathogenic 
bacteria, 
Toxoplasma 
N.D. 
TLR12 N.D.  N.D. 
TLR13 N.D.  N.D. 
HSP heat shock protein; N.D. not determined. Original references are listed in the review article (Ishii 
et al., 2006). 
 
Toll-like receptors are expressed by a variety of immune and non-immune cells. Myeloid cells 
constitutively express TLR1 and TLR6, macrophages preferentially express TLR2, 3, 4 and 8 
(in humans), and B cells express TLR7, 9 and 10. CD4+ T cells and natural killer cells were 
reported to express TLR2, and some publications describe the expression of TLR2, 3, 5, and 
9 on T cells (Ishii et al., 2006; Kabelitz, 2007). TLR expression on DC differs considerably 
between mice and men: human myeloid DC and monocyte-derived DC express all TLRs with 
the exception of TLR9 and therefore recognize a variety of pathogenic molecular patterns. 
The repertoire of TLRs expressed by plasmacytoid DC (TLR1, 6, 7, and 9) complements the 
TLRs on mDC, enabling the two subsets of DC to respond to distinct microorganisms. Murine 
DC subsets exhibit a broader distribution of TLR expression, with mouse pDC expressing all 
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TLRs but TLR3 and 4. In contrast to human DC, TLR9 and 7 are expressed by most subsets 
of DC, with the exception of CD8+ DC, which lack TLR7. The expression pattern of TLRs on 
DC is reviewed in Mazzoni and Segal, 2004.  
 
While Toll-like receptors have been known only for the last decade, their ligands have been 
used as adjuvant components in vaccine formulations for a long time. Due to their efficacy in 
activating immune cells, TLR ligands are currently being used in clinical trials as adjuvants in 
protective vaccinations against bacterial and viral infections and in anti-tumor vaccines. 
However, recent studies suggest that tumor cells also bear TLRs and that TLR signaling may 
promote tumor growth and immune evasion (Huang et al., 2005; Kelly et al., 2006). 
2.2.2 Signaling pathways of Toll-like receptors 
TLRs belong to a superfamily called the Toll/IL-1 receptor (TIR) family. They are type I 
transmembrane receptors characterized by a highly variable extracellular region containing a 
leucine-rich repeat domain involved in ligand binding and an intracellular tail containing a 
highly conserved TIR homology domain which mediates homo-and heterophilic interactions 
between TLRs and TIR-containing adapters. Most TLRs signal through a common pathway, 
the MyD88 (myeloid differentiation primary response gene 88) -dependent pathway (Figure 
2.4). Following TLR ligation, the adaptor protein MyD88 is recruited to the receptors by TIR-
TIR interactions. The observation that MyD88-deficient mice still react to LPS suggested 
other adaptors involved in TLR4 signaling (Kawai et al., 2001). The discovery of the second 
TIR domain-containing adaptor, MyD88 adaptor-like (Mal), indicated a potential specificity in 
the signaling pathways of different TLRs, particularly when Mal was shown to have a role in 
TLR2 and TLR4 signaling but not in responses to other TLR ligands. Signaling via MyD88 as 
well as Mal eventually activates the IKK (inhibitor of κB kinase) complex. The IKK complex 
catalyzes IκB (inhibitor of κB) phosphorylation and degradation, thus allowing NF-κB to 
translocate into the nucleus. In addition, upstream kinases for p38 and JNK are activated, 
leading to the activation of AP-1 (activated protein 1). NF-κB and AP-1 control inflammatory 
responses by inducing proinflammatory cytokine expression. 
 
TLR3 is the only TLR which signals only through the MyD88-independent pathway. A third 
adaptor, termed TIR-related adaptor protein inducing interferon (TRIF), is recruited by both 
TLR4 and TLR3, and is responsible for the activation of IRF3. The discovery of TRIF 
provided the first molecular basis for why TLR3 and TLR4 are able to induce the production 
of IFN-β. The fourth adaptor to be described was named TRIF-related adaptor molecule 
(TRAM), and acts only in TLR4 signaling, where it interacts with TRIF. These current articles 
Introduction 
17 
review Toll-like receptor signal transduction (Chen et al., 2008; Doyle and O'Neill, 2006; 
Krishnan et al., 2007; O'Neill, 2006). Figure 2.4 shows a schematic representation of the TLR 
adaptors and most important signaling molecules.  
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Figure 2.4: Overview of the TLR adaptors and main signaling molecules. 
On TLR ligation, TLR4, 7, 8, and 9, and TLR2-TLR1 or TLR2-TLR6 heterodimers recruit MyD88 to 
their TIR domains. MyD88 binds IRAK4, which phosphorylates IRAK1, which in turn binds TRAF6 and 
other kinases. Subsequent ubiquitination and phosphorylation initiates the activation of the IKK 
complex and via IκB degradation the translocation of NF-κB into the nucleus. In the MyD88-
independent pathway, TLR3 recruits TRIF directly to its TIR domain while TLR4 recruits TRAM which 
in turn recruits TRIF. TRIF binds TRAF6 directly in an IRAK1/4-independent manner. TRIF can also 
activate IRF3. IRAK IL-1R-associated kinase, IRF interferon regulatory factor, MyD88 myeloid 
differentiation primary response gene 88. 
 
Stimulation of cells through TLR-dependent pathways converges at the activation of the 
transcription factors NF-κB, IRF3, 7, and 5, and AP-1. These transcription factors collaborate 
in the production of a large number of cytokines, whose promoters contain multi-transcription 
factor binding sites leading to a highly specific activation. While NF-κB and AP-1 induce the 
expression of most proinflammatory cytokines (IL-1β, IL-6, IL-10, IL-12, IP-10, and TNF), the 
regulation of type I interferons is regulated by the IRF family of transcription factors. 
However, the IFN regulation seems to differ between cell types. In mDC, TLR signal 
transduction via TLR3 or 4 and TRIF leads to the expression of IFN-β, which in turn can 
induce the production of IRF7 and thus the secretion of IFN-α in an autocrine or paracrine 
manner (Au et al., 1998). Regulation of IFN production in pDC, however, is entirely different. 
Comparisons between IRF3-/- pDC and IRF7-/- pDC revealed that IFN production by TLR7, 8, 
and 9 was normal in IRF3-/- cells, but completely ablated in IRF7-/- cells, indicating that IRF7 
is essential for type I interferon induction in pDC (Honda et al., 2005).  
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2.3 Objectives 
In the field of cancer immunotherapy, dendritic cells have emerged as a powerful tool to 
initiate T-cell responses, induce immunological memory and break immunological tolerance 
to tumors. The ability of DC-based vaccines to stimulate cytotoxic T cells and to polarize T 
helper cells towards a Th1 profile highlights their potential in the immunotherapy of cancer. 
However, despite rapid progress in the field of DC biology, clinical responses to DC 
vaccination have yet to meet expectations. Current research addresses the optimization of 
the different steps involved in the generation of DC vaccines. In the present study, DC were 
differentiated in the presence of the hematopoietic growth factor Flt3L (FL-DC) in order to 
generate both myeloid and plasmacytoid dendritic cell subsets. The first focus of this study 
was the development of an effective strategy for DC maturation. The kinetics of DC 
maturation are a critical factor, as immature DC carry the risk of inducing tolerance whereas 
extensive stimulation may lead to DC unresponsiveness and exhaustion. To optimize the DC 
maturation process, FL-DC were activated for a short versus a prolonged period by the TLR9 
ligand CpG and analyzed for their capacity to elicit immune responses in vitro and in vivo.  
 
In addition, DC maturation with TLR7 ligands was analyzed in more detail. This strategy is a 
more promising approach when dealing with human cells because of the restricted 
expression pattern of TLR9 on human DC. Although TLR7 and TLR9 stimulation are thought 
to activate the same intracellular signaling pathways, mDC generated by the Flt3L DC culture 
selectively fail to secrete detectable amounts of IL-12p70 after TLR7 stimulation. Due to the 
imperative of IL-12p70 secretion for the induction of efficient cell-mediated and Th1-based 
immune responses, the mechanisms underlying the deficient IL-12p70 production upon 
TLR7 stimulation were examined by means of inhibition of signal transduction, knock-out 
mice, and a genome-wide expression analysis by microarray. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Materials and methods 
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3.1 Materials 
3.1.1 Technical equipment 
Agilent Bioanalyzer 2100   Agilent, Palo Alto, USA 
Alpha Imager (gel documentation)  Alpha Innotech, San Leandro, USA 
Balance (LP 6209)    Sartorius, Göttingen, Germany 
BeadStation 500 (microarray reader) Illumina, Essex, United Kingdom 
Cell culture CO2 incubator (BD 6220) Heraeus, Hanau, Germany 
Cell culture laminar flows   Heraeus, Hanau, Germany 
Centrifuge 5424     Eppendorf, Hamburg, Germany 
FACSCalibur     Becton Dickinson, San Jose, USA 
Fluo-Link (UV irradiation)   Vilber Lourmat, Marne La Vallée, France 
Gel electrophoresis systems   Bio-rad, Munich, Germany 
MiniMACS, QuadroMACS   Miltenyi Biotec, Bergisch Gladbach, Germany 
Mithras LB940 multilabel plate reader Berthold Technologies, Bad Wildbad, Germany 
Multifuge 3L-R    Heraeus, Hanau, Germany 
Nanodrop ND-1000    NanoDrop, Wilmington, USA 
Neubauer hemocytometer   Optik Labor Frischknecht, Balgach, Germany 
pH meter     WTW, Weilheim, Germany 
Power Supply 200/2.0   Bio-rad, Munich, Germany 
Refrigerators (4°C, -20°C)   Bosch, Gerlingen-Schil lerhöhe, Germany 
Refrigerators (-80°C)    Thermo Scientific, Waltham , USA 
Shaker     NeoLab, Heidelberg, Germany 
Thermocycler T3    Biometra, Göttingen, Germany 
Thermomixer     Eppendorf, Hamburg, Germany 
Vortex VF2     Janke & Kunkel, Staufen, Germany 
3.1.2 Chemicals, reagents and buffers 
Agarose LE     Biozym, Hess. Oldendorf, Germany 
Aqua ad injectabilia    Braun Melsungen AG, Melsungen, Germany 
Bovine serum albumine (BSA)  Sigma Aldrich, Steinheim, Germany 
Brefeldin A     Sigma Aldrich, Steinheim, Germany 
Chloroform     Sigma Aldrich, Steinheim, Germany 
Dimethyl sulfoxide (DMSO)   Sigma Aldrich, Steinheim, Germany 
Dulbecco’s PBS (1x)    PAA, Pasching, Germany 
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Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSSafe   Becton Dickinson, Heidelberg, Germany 
Heparin-Natrium Braun 25000 I.E./5 ml B. Braun Melsungen AG, Melsungen, Germany 
Illumina TotalPrep RNA Amplification Kit Applied Biosystems, Foster City, USA 
Isoflurane (Forene®)    Abbott, Zug, Switzerland 
Isopropanol (70 Vol%)   Apotheke Innenstadt, LMU Munich 
Mouse-6 v1.1 Expression Bead Chips Illumina, Essex, United Kingdom 
Paraformaldehyde (PFA)   Sigma Aldrich, Steinheim, Germany 
PharmLyse (10x) RBC lysis   Becton Dickinson, Heidelberg, Germany 
Sigma fast OPD tablet sets   Sigma Aldrich, Steinheim, Germany 
Sodium azide (NaN3)    Sigma Aldrich, Steinheim, Germany 
Sodium chloride (NaCl 0.9%)  Baxter S. A., Lessines, Belgium 
Sulfuric acid (H2SO4, 2N)   Apotheke Innenstadt, LMU Munich 
TMB Substrate Reagent Set   Becton Dickinson, Heidelberg, Germany 
Trizol reagent     Invitrogen, Carlsbad, USA 
Trypan blue     Sigma Aldrich, Steinheim, Germany 
Trypsin (10x)     PAA, Pasching, Austria 
Tween 20     Roth, Karlsruhe, Germany 
 
MACS buffer     Fixation buffer for FACS samples 
2 mM EDTA     2% PFA 
10% FCS     in PBS 
in PBS 
 
ELISA coating buffer 1   ELISA coating buffer 2 
0.2 M sodium phosphate   0.1 mM sodium carbonate 
in water     in water 
pH 6.5      pH 9.5 
 
ELISA assay diluent     ELISA wash buffer 
10% FCS      0.05% Tween 20 
in PBS      in PBS 
pH 7.0 
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3.1.3 Kits 
Cell proliferation ELISA, BrdU  Roche, Mannheim, Germany 
Cell Trace CFSE Cell Proliferation Kit Invitrogen/Molecular Probes, Eugene, USA 
 
Cytokine ELISA sets 
IFN-γ murine     BD Bioscences, San Diego, USA 
IL-4 murine     BD Bioscences, San Diego, USA 
IL-6 murine     BD Bioscences, San Diego, USA 
IL-10 murine     BD Bioscences, San Diego, USA 
IL-12p40 murine    BD Bioscences, San Diego, USA 
IL-12p70 murine    BD Bioscences, San Diego, USA 
IP-10 murine     R & D Systems, Minneapolis, USA 
 
Cytokine ELISA antibodies 
Detection of murine IFN-α: 
Capture Ab: Anti-IFN-α (RMMA-1)  PBL, New Brunswick, USA 
Detection Ab: Anti-IFN-α (polyclonal,  PBL, New Brunswick, USA 
 rabbit anti mouse) 
HRP-conjugated F(ab´)2 fragments   Biomeda, Foster City, USA 
 (donkey anti rabbit) 
Detection of murine immunoglobulins: 
Anti-IgG (polyclonal, goat anti mouse) Southern Biotech, Birmingham, USA 
Anti-IgG1 (polyclonal, goat anti mouse) Southern Biotech, Birmingham, USA 
Anti-IgG2a (KLH/G2a-1-1)   Southern Biotech, Birmingham, USA 
 
MACS cell separation 
CD4 Micro Beads    Miltenyi Biotec, Bergisch Gladbach, Germany 
CD11c MicroBeads    Miltenyi Biotec, Bergisch Gladbach, Germany 
CD45R/B220 MicroBeads   Miltenyi Biotec, Bergisch Gladbach, Germany 
Regulatory T Cell Isolation Kit  Miltenyi Biotec, Bergisch Gladbach, Germany 
LS, MS and LD columns   Miltenyi Biotec, Bergisch Gladbach, Germany 
3.1.4 Cell culture reagents and media 
β-Mercaptoethanol    Sigma-Aldrich, Steinheim, Germany 
Dulbecco's modified Eagle´s medium PAA, Pasching, Austria 
 (DMEM), high glucose 
Materials and methods 
24 
Fetal calf serum (FCS)   GibcoBRL (invitrogen), Karlsruhe, Germany 
Hank's balanced salt solution (HBSS) PAA, Pasching, Austria 
L-glutamine 200mM    PAA, Pasching, Austria 
MEM-NEAA (non-essential amino acids) GibcoBRL (invitrogen), Karlsruhe, Germany 
Phosphate buffered saline (PBS)  PAA, Pasching, Austria 
Penicillin / Streptomycin (100x)  PAA, Pasching, Austria 
Ovalbumin from chicken egg   Sigma-Aldrich, Steinheim, Germany 
OVA257-264 peptide (SIINFEKL)  Metabion, Martinsried, Germany 
Roswell Park Memorial Institute (RPMI) PAA, Pasching, Austria 
 1640 medium 
SB203580 (p38 inhibitor)   Invivogen, San Diego, USA 
Sodium pyruvate    PAA, Pasching, Austria 
Survivin protein    Generated in HEK293 cells, kindly provided by 
       Jiwu Wei and Raffaela Tyroller 
T1Db peptide (SAINNYAQKL)  Metabion, Martinsried, Germany 
VLE RPMI 1640 medium (very low   Biochrom, Berlin, Germany 
 endotoxin) 
 
C26 medium     DC medium 
10% FCS     10% FCS 
2 mM L-glutamine    2 mM L-glutamine 
100 IU/ml penicillin    100 IU/ml penicillin 
100 µg/ml streptomycin   100 µg/ml streptomycin 
in DMEM     in RPMI 1640 
 
DC complete medium 
10% FCS 
2 mM L-glutamine 
100 IU/ml penicillin 
100 µg/ml streptomycin 
1 mM sodium pyruvate 
1% non-essential amino acids (MEM-NEAA) 
3.75 x 10-4 % β-mercaptoethanol 
in VLE RPMI 1640 
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Cytokines, growth factors, TLR ligands and stimuli 
anti-CD3     BD Biosciences, San Diego, USA 
 (clone 500A2, syrian hamster IgG2,κ) 
CCL21, mouse recombinant   tebu-bio, Offenbach, Germany 
CpG 1826 (CpG)    Coley Pharmaceuticals, Langenfeld, Germany 
 (5’-TCCATGACGTTCCTGACGTT-3’) 
Flt-3 ligand (Flt3L), human recombinant tebu-bio, Offenbach, Germany 
Granulocyte-macrophage colony-  tebu-bio, Offenbach, Germany 
 stimulating factor (GM-CSF), mouse recombinant 
Interleukin-4 (IL-4), mouse recombinant tebu-bio, Offenbach, Germany 
Resiquimod (R848)    Alexis Biochemicals, Lausen, Switzerland 
 
Expendable plastic materials for cell culture experiments were purchased from Becton 
Dickinson (Heidelberg, Germany), Bibby Sterrilin (Stone, Staffordshire, Great Britain), 
Corning (Corning, USA), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, Germany), 
Greiner (Frickenhausen, Germany), Henke-Sass Wolf (Tuttlingen, Germany) or Sarstedt 
(Nümbrecht, Germany). 
3.1.5 FACS antibodies and MHC class I pentamers 
Description Isotype Clone Company 
anti-CD4 Rat (DA) IgG2a,κ RMA4-5 BD Biosciences 
anti-CD8a Rat (LOU/Ws1/M) IgG2a,κ 53-6.7 BD Biosciences 
anti-CD11b Rat (DA) IgG2b,κ M1/70 BD Biosciences 
anti-CD11c Armenian Hamster IgG1a, λ2 HL3 BD Biosciences 
anti-CD25 Rat (Lewis) IgM, κ 7D4 BD Biosciences 
anti-CD40 Armenian Hamster IgM, κ HM40-3 BD Biosciences 
anti-CD45R/B220 Rat IgG2a,κ RA3-6B2 BD Biosciences 
anti-CD69 Armenian Hamster IgG1, λ3 H1.2F3 BD Biosciences 
anti-CD80 (B7-1) Armenian Hamster IgG2, κ 16-10A1 BD Biosciences 
anti-CD86 (B7-2) Rat (Louvain) IgG2a,κ GL1 BD Biosciences 
anti-CD197 (CCR7) Rat IgG2a,κ 4B12 BioLegend 
anti-H2Db (MHC I) Mouse (Balb/c) IgG2b,κ KH95 BD Biosciences 
anti-H2Dd (MHC I) Mouse (C3H/HeJ) IgG2a,κ 34-2-12 BD Biosciences 
anti-Ly6C Rat IgM, κ AL-21 BD Biosciences 
anti-MHC II Rat IgG2b NIMR-4 Southern Biotech 
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isotype controls   BD Biosciences 
Pro5-OVA257-264-H2Kb OVA257-264-H-2Kb pentamers  Proimmune 
3.1.6 Software 
Adobe Creative Suite    Adobe Systems, San Jose, USA 
CellQuest     BD Biosciences, San Diego, USA 
FlowJo     Tree Star, Ashland, USA 
Microsoft Office    Microsoft, Redmond, USA 
NCBI Entrez Gene    www.ncbi.nlm.nih.gov/sites/entrez?db=gene 
Pathway Studio    Ariadne Genomics, Rockville, USA 
SPSS      SPSS, Chicago, USA 
 
 
3.2 Cell culture 
3.2.1 General culture conditions 
All cell lines were cultured in tissue culture flasks at 37°C in a humidified atmosphere and 
5% CO2. All manipulations were performed with sterile reagents under a laminar flow hood. 
Cell concentration and viability was determined by Trypan blue staining. Trypan blue is not 
absorbed in a viable cell; however, it traverses the membrane in a dead cell. Hence, dead 
cells are shown as a distinctive blue color under the microscope. Cell suspensions were 
mixed with 0,25% Trypan blue in PBS at appropriate dilutions and counted in a Neubauer 
hemocytometer under the microscope. Cell number was calculated as follows: 
 
Cells/ml = (number of cells counted) x (dilution factor) x 104  
3.2.2 C26 colon carcinoma cell line 
The murine colon carcinoma cell line C26 (Cell Lines Service, Heidelberg, Germany; first 
described in Griswold and Corbett, 1975) was grown in C26 medium and split in a 1:2 
dilution three times a week. Cells were detached with cell scrapers, centrifuged (370 g, 
7 min, 4°C), resuspended with a 20 G needle in fres h medium and transferred to culture 
flasks. 
Materials and methods 
27 
3.2.3 Dendritic cells 
3.2.3.1 Generation of bone-marrow-derived dendritic cells 
Immature murine DC were generated from bone marrow as described(Brasel et al., 2000; 
Brawand et al., 2002), with some modifications. Briefly, bone marrow cells were isolated as 
described in chapter 3.4.2.3, p. 35 and diluted to 1 x 106 cells/ml in DC medium 
supplemented with GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) to generate myeloid DC 
(GM-DC). On day 4, fresh medium with GM-CSF and IL-4 was added (40% of the original 
volume). Two days later (d 6), differentiated DC were gathered by collecting the supernatant 
and rinsing the flasks with cold PBS to detach loosely adherent cells. DC (CD11c+ cells) 
generally represented > 75% of the preparation.  
 
To generate a mixture of plasmacytoid and myeloid DC, bone marrow cells were cultured at 
2 to 3 x 106 cells/ml in DC complete medium containing 20 ng/ml recombinant Flt3L for 7 to 8 
days and harvested as described above (FL-DC). DC (CD11c+ cells) generally represented > 
80% of the preparation with typically 40% being plasmacytoid DC (B220+) and 60% being 
myeloid DC (B220-, CD11b+).  
 
Figure 3.1 shows representative flow cytometry dot plots of GM-CSF / IL-4 DC in comparison 
to FL-DC. DC generated with GM-CSF and IL-4 are usually bigger (higher forward scatter, 
FSC) and more granular (higher side scatter, SSC) than FL-DC (Figure 3.1 A). They 
comprise only mDC, which do not express B220 (Figure 3.1 B) but high levels of CD11b 
(Figure 3.1 C). FL-DC on the other hand consist of mDC and pDC. pDC are characterized by 
a high expression of B220 and a low expression of CD11b. Gating of mDC and pDC for 
subsequent analysis of subsets was done according to their expression of B220, CD11b and 
CD11c. 
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Figure 3.1: Comparison of GM-CSF / IL-4 DC and FL-DC. 
Murine bone marrow cells were differentiated either with GM-CSF and IL-4 (left panel) or with Flt3L 
(right panel). Representative flow cytometry data is shown as dot plots. (A) Live gates were drawn in 
FSC-SSC plots to exclude dead cells or unneeded cell populations. (B) CD11c is expressed on all 
subsets of murine DC and the characteristic marker for DC. B220 (CD45R) is only expressed on pDC, 
which are not generated in GM-CSF / IL4 cultures. (C) mDC express high levels of CD11b, whereas 
pDC have low levels or no CD11b expression. Numbers show percentage of the indicated subset 
relative to live cells. 
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3.2.3.2 Antigen loading of dendritic cells 
Differentiated DC were harvested on day 6 (GM-CSF / IL-4 DC) or 7 (FL-DC) and pulsed with 
antigen to elicit specific immune responses in vaccinated animals. In this study, peptides, 
proteins and inactivated tumor cells were used as antigen sources. DC were pulsed with 
100 nM peptide antigen (OVA257-264 peptide, SIINFEKL) for one hour before using the cells 
for vaccination or in vitro assays. For in vitro assays, T1Db peptide (SAINNYAQKL) derived 
from the SV40 large T antigen was used as a negative control to test for antigen-specificity of 
T-cell responses. To test the ability of DC to cross-present protein antigens or to induce T 
helper cell responses, 100 µg/ml ovalbumin protein was added to immature DC 24 h before 
cells were matured with CpG. In in vitro assays, survivin protein was used as negative 
control. For the presentation of tumor antigens on DC, C26 tumor cells were first UV-
irradiated at 0.7 J/cm2 in a UV-crosslinker (Fluo-Link) and then added to immature DC in a 
ratio of 1:5 24 h before CpG stimulation. 
3.2.3.3 In vitro activation of dendritic cells 
DC were activated with the oligodeoxynucleotide CpG 1826 (CpG) as ligand for TLR9, with 
CL087 as TLR7 ligand, or with R848 (resiquimod) as ligand for TLR7 that also activates 
TLR8 in humans. DC that were used for in vitro analysis or RNA isolation were activated with 
3 µg/ml CpG, 1 µg/ml CL087 or 0.5 µg/ml R848 for 2 to 48 h as indicated. For the inhibition 
of p38 MAPK, SB203580 (1.25 µM or 2.5 µM as indicated) was added to DC cultures 30 min 
before cells were stimulated with R848. Antigen-pulsed DC that were used to vaccinate mice 
were stimulated with 6 µg/ml CpG for 4 h or 20 h before injection, as indicated.  
3.2.4 Isolation of DC and T-cell subtypes by magnetic cell separation (MACS) 
MACS (magnetic cell separation or magnetic-activated cell sorting) is used for the isolation of 
viable and functionally active cells by magnetic labeling. The mixture of cells to be separated 
is incubated with magnetic beads (superparamagnetic particles of approximately 50 nm 
diameter) coated with antibodies against a particular surface antigen. This causes the cells 
expressing this antigen to attach to the magnetic beads. Afterwards, the cell solution is 
transferred on a column placed in a strong magnetic field. In this step, the cells attached to 
the beads (expressing the antigen) are retained on the column, while other cells (not 
expressing the antigen) flow through. The retained cells are eluted from the column after 
removal from the magnet. With this method, cells can be separated positively or negatively 
with respect to the particular antigen. In this study, reagents from Miltenyi Biotec were used 
according to the manufacturer’s instructions. Plasmacytoid DC were sorted from FL-DC by 
positive selection using B220 microbeads, while myeloid DC differentiated by Flt3L were 
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obtained by depleting B220+ plasmacytoid DC from FL-DC. For the analysis of DC migration 
in vivo, DC were separated from total spleen cells with CD11c beads. To examine T helper 
cell responses, CD4+ T cells were isolated from splenocytes with CD4 beads. For the positive 
selection of labeled cells, LS and MS columns were used. Cells were labeled with the 
respective microbeads in MACS buffer for 15 min at 4°C and washed with MACS buffer. LS 
columns were placed in the appropriate magnet and rinsed with 3 ml MACS buffer prior to 
loading the cells in a volume of 2 ml. Columns were washed three times with 3 ml MACS 
buffer. Effluent from cells and the first wash was gathered as negative fraction, flowthrough 
from the second and third wash was discarded. Positive cells were eluted by flushing the 
cells in 2 ml MACS buffer through the column dislodged from the magnet with the supplied 
plunger. To further enrich positively labeled cells, eluted cells were applied on a MS column 
which had been placed in a magnet and rinsed with 1 ml MACS buffer. Columns were 
washed twice with 1 ml MACS buffer and total effluent was discarded. Cells were flushed out 
in a volume of 1 ml after removing the column from the magnet. To increase the purity of 
negatively sorted mDC from FL-DC cultures, the negative flowthrough from LS columns was 
applied to LD columns which had been placed in a magnet and rinsed with 2.5 ml MACS 
buffer. Columns were washed with 2 ml MACS buffer and total effluent was gathered as 
myeloid DC (depleted from plasmacytoid DC). Regulatory T cells were isolated from spleen 
cells by first depleting non-CD4+ cells and subsequent positive selection of CD4+ CD25+ 
regulatory T cells using the Regulatory T Cell Isolation Kit according to the manufacturer’s 
instructions. 
3.2.5 Assessment of T-cell responses in vitro 
Induction of antigen-specific proliferation of T cells was measured by 5’-Bromo-2’-deoxy-
uridine (BrdU) ELISA. This technique is based on the incorporation of the pyrimidine 
analogue BrdU instead of thymidine into the DNA of proliferating cells. After its incorporation 
into DNA, BrdU is detected by immunoassay. For this purpose, FL-DC were pulsed with 
different concentrations of ovalbumin (OVA) for 18 h before activation with CpG for 0, 4 or 20 
hours. For the last hour of stimulation, unpulsed DC were cultured with OVA257-264 peptide 
(SIINFEKL). Antigen-specific T-cell responses were analyzed by using transgenic mice 
expressing a T-cell receptor specific for OVA. OT-I mice express the specific T-cell receptor 
recognizing SIINFEKL bound to MHC class I complexes on CD8+ T cells, while OT-II mice 
were used to analyze CD4+ T-cell responses as they have OVA-specific T helper cells. To 
confirm antigen-specificity of T-cell responses, DC were pulsed with T1Db peptide 
(SAINNYAQKL) or survivin protein as irrelevant control antigen.  
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To analyze cytotoxic T-cell proliferation, 2 x 105 splenocytes from OT-I mice were cocultured 
with the indicated number of washed FL-DC for 48 h before 7.5 µM BrdU was added for the 
last 6 to 12 h of culture. Cell culture plates were centrifuged (300 g, 5 min) and medium was 
removed by flicking off before plates were dried with a hairdryer. Cell fixation, incubation with 
anti-BrdU antibody and substrate reaction were done according to the manufacturer’s 
instructions. Chemiluminescence was measured in duplicate in relative light units (rlu) with a 
multilabel plate reader. IFN-γ secretion of CTL was measured in the supernatants of these 
cocultures by ELISA to check for functionality of CTL. 
 
To analyze the induction of Th1 versus Th2 responses, splenocytes from OT-II mice were 
magnetically sorted using CD4 MicroBeads according to the manufacturer’s instructions and 
1 x 105 CD4 T cells were cocultured with the same number of FL-DC. After 48 h, 
supernatants were tested for IFN-γ (as an indicator for Th1 responses) and IL-4 
concentrations (as a marker for Th2 responses) by ELISA. 
3.2.6 Analysis of DC-induced suppression of regulatory T-cell function 
For regulatory T-cell suppression assays, CD4+ CD25- effector cells and CD4+ CD25+ 
regulatory T cells were sorted by MACS. The purity of Treg cells was typically greater than 
97%. CD4+ CD25- effector T cells (7.5 x 104 cells per well) were cultured in the presence of 
0.1 µg/ml soluble anti-CD3 antibody with 6 x 104 CD4+ CD25+ Treg cells and 3.5 x 103 FL-DC. 
BrdU incorporation was measured in triplicate as described above and is shown in rlu. 
Suppression of T-cell proliferation by Treg cells in coculture with unstimulated DC is defined 
as 100 % suppression. Suppression was calculated as follows: 
 
Suppression (% of control) = [1-(rlu with Treg / rlu without Treg)] / [1-(rlu of unstimulated DC 
with Treg / rlu of unstimulated DC without Treg)]. 
3.2.7 Transwell migration assays 
To assess the potential of DC to migrate towards CCL21, a cytokine strongly expressed in 
T-cell zones of spleen and lymph nodes, 2 x 104 FL-DC in 100 µl DC complete medium were 
put into 5 µm transwell inserts, placed into 24-well plates containing 600 µl DC complete 
medium with or without 100 ng/ml CCL21, and incubated for 2 hours at 37°C. The medium in 
the lower chambers was concentrated to 50 µl and cells were counted with a 
hemocytometer. Percentages of migrated DC are shown as means of triplicate samples. 
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3.3 Immunological methods 
3.3.1 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay, or ELISA, is a technique used to detect the presence 
of an antibody or an antigen in a sample by enzyme-linked antibodies and the subsequent 
conversion of a colorless substrate to a colored reagent (first described by Engvall and 
Perlmann, 1971). 
3.3.1.1 Cytokine ELISA 
In this study, cytokines in cell culture supernatants were detected by sandwich ELISA: plates 
were coated with an antibody directed against the respective cytokine, and bound cytokines 
were revealed by a second, biotinylated antibody followed by streptavidin coupled to 
peroxydase. This enzyme catalyzes the oxidation of 3,3’,5,5’ – tetramethylbenzidine (TMB) 
with hydrogen peroxide to a blue chromogen. The detection of all cytokines except IFN-α 
was done with kits including all the necessary reagents according to the manufacturers’ 
instructions. Samples were generally diluted 1:2. For IL-12p40 and IFN-γ ELISAs, samples 
were diluted 1:5 and 1:10, respectively. 
 
Detection of IFN-α was done by a set of antibodies: plates were coated overnight at 4°C with 
50 µl/well capture antibody in coating buffer (1 µg/ml). Unspecific binding sites on the plates 
were blocked with 150 µl/well assay diluent for 3 h at room temperature (RT). The plates 
were washed 3 times with wash buffer, before samples and standard protein were loaded on 
the plates and incubated overnight at 4°C. The high est standard was 105 IU/ml, samples 
were applied undiluted. Plates were washed again, and 50 µl/well detection antibody in 
assay diluent (625 ng/ml) was added for 3 h at RT. Horseradish peroxidase (HRP)-
conjugated F(ab´)2 fragments (15 µg/ml) were used to detect bound detection antibody after 
washing the plates 10 times and incubated 3 h at RT. To develop a colored reaction, TMB 
and H2O2 were used as substrate for the HRP. 50 µl/well substrate solution were added to 
each well after washing the plates again 10 times, and the reaction was stopped by adding 
25 µl/well of 2N H2SO4. All cytokine ELISAs were read at 450 nm with a wavelength 
correction subtraction at 590 nm. 
3.3.1.2 Measurement of immunoglobulin concentrations in mouse sera 
Serum antibody titers were determinded by coating 96-well ELISA plates with antigen 
(ovalbumin, 10 µg/ml in PBS) overnight at 4°C. Unsp ecific binding sites were blocked with 
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150µl/well assay diluent for 1 h at RT. Plates were washed 3 times with wash buffer before 
50 µl/well of each sample were loaded in duplicate (mice sera, 1:100 diluted in PBS) and 
incubated for 1 h before plates were washed again. 50 µl/well anti-mouse antibodies coupled 
to HRP were added to detect the bound immunoglobulins and incubated for 1 h: anti-IgG 
(binds to all IgG subclasses) and anti-IgG1 were used in a 1:1000 dilution, whereas anti-
IgG2a was diluted 1:4000 in PBS. After washing the plates 5 times, OPD substrate tablets 
(o-phenylenediamine dihydrochloride and urea hydrogen peroxide) dissolved in water were 
added to the wells and the reaction was developed for 5 to 20 min before it was stopped with 
2N H2SO4. Plates were read at 490 nm with a wavelength correction subtraction at 690 nm. 
3.3.2 Flow cytometry 
Flow cytometry is a method that allows for the analysis of various properties of single cells or 
particles suspended in a fluid. The suspension of single cells emerges from the sample 
needle into a surrounding sheath fluid liquid that is moving with a greater velocity. The 
resulting acceleration at the orifice forces the particles to travel one by one in the central 
portion of the fluid jet that emerges from the flow chamber. This principle is called 
hydrodynamic focusing. The cells flow past the detector point and are illuminated by a 
focused laser beam. The illuminating light is scattered and simultaneously, if particles have 
been previously stained with a fluorescent dye capable of absorbing the illuminating light, 
fluorescence emission occurs. Scattered light and emitted fluorescence are collected and 
sent to different detectors by using optical filters. The relative size and granularity of a cell 
influence the way in which light is scattered as the cell passes through the laser beam. Low 
angle scattered light depends on cell size and is recorded as a parameter called forward 
scatter (FSC). Similarly, cell granularity and surface convolutions scatter light at higher 
angles. For convenience the signal is measured orthogonal to the stream and is referred to 
as side scatter (SSC). Fluorescence measurements are also made in the orthogonal 
direction with detectors appropriate to the specific emission spectrum of the fluorochrome. All 
measurements were performed on a FACSCalibur, where cells are illuminated by a 488 nm 
argon-ion laser to detect the following fluorochromes: fluorescein isocyanate (FITC, emission 
at 520 nm), phycoerythrin (PE, emission at 575 nm), and peridinin chlorophyll protein 
(PerCP, emission at 675 nm). A red diode laser was used to excite allophycocyanin (APC, 
emission at 660 nm). 
3.3.2.1 Analysis of surface molecule expression 
Expression of surface molecules was analyzed by staining 2 x 105 to 2 x 106 cells in 200 µl 
PBS or cell culture medium with fluorochrome-conjugated monoclonal antibodies against the 
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examined surface antigens for 25 min at 4°C (0.5 µl  per antibody; see chapter 3.1.5, p. 25 for 
an overview of utilized antibodies). Cells were washed twice with PBS before data was 
acquired on a FACSCalibur. When cells were not analyzed immediately, they were 
resuspended in 200 µl fixation buffer and kept at 4°C until data was collected by flow 
cytometry. FlowJo software was used to analyze data. 
3.3.2.2 MHC pentamer staining 
Multimeric MHC-peptide complexes have a high avidity for T-cell receptors of a particular 
specificity as determined by the MHC allele and peptide combination, and their use as 
detection reagent allows the evaluation of specific T-cell immunity. To detect antigen-specific 
CD8+ T-cell responses, 200 to 300 µl peripheral blood were incubated with 1 ml red blood 
cell lysis buffer for 8 min at RT. Cells were washed with PBS and resuspended in 50 µl PBS, 
before 4 µl Pro5-OVA257-264-H-2kb-PE pentamer were added and incubated for 15 min at RT. 
Cells were washed with PBS before surface staining was done with an anti-CD8 antibody as 
described above.  
3.3.2.3 CFSE staining 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a dye often used to trace cells. 
The colorless molecule passively diffuses into cells, where the acetate groups are cleaved by 
esterases to yield highly fluorescent carboxyfluorescein succinimidyl ester. The succinimidyl 
ester groups then react with intracellular amines, forming fluorescent conjugates. The dye-
protein adducts that form in labeled cells are retained by the cells throughout development 
and are inherited by daughter cells after cell division. Cells were resuspended in 1 ml HBSS 
and labeled with 15 µl 0.1 to 1 mM CFSE for 15 min at 37°C. Cells were washed and injected 
either subcutaneously to trace migration of DC or intravenously to analyze antigen-specific 
lysis of target cells. To detect labeled cells after injection, single cell suspensions were 
generated from appropriate organs and analyzed by flow cytometry. CFSE is detected in the 
FL1 channel. 
 
3.4 Animal experimentation 
3.4.1 Animals 
Female balb/c and C57BL/6 mice were purchased from Harlan-Winkelmann (Borchen, 
Germany). Transgenic and knock-out mice mice were kindly provided by Prof. Th. Brocker 
(Institute of Immunology, Ludwig-Maximilian University Munich, Germany: TCR transgenic 
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OT-I and OT-II mice), Prof. J. Heesemann (Max von Pettenkofer Institute for Hygiene and 
Medical Microbiology, Ludwig-Maximilian University Munich, Germany: IL-10-deficient mice), 
Prof. S. Frantz (Medizinische Klinik und Poliklinik I, University Würzburg, Germany: p50-
deficient mice), and Dr. A. Krug (Department of Internal Medicine II, Klinikum Rechts der 
Isar, Technical University Munich, Germany: IRF3/7-deficient mice). Mice were 6 to 10 
weeks of age at the onset of experiments. Mice were anesthetized with isoflurane for all 
interventions but subcutaneous (s.c.) injections. All animal studies were approved by the 
local regulatory agency (Regierung von Oberbayern, Munich, Germany). 
3.4.2 Organ and single cell preparation 
3.4.2.1 Preparation of serum and isolation of blood cells 
For the detection of specific antibodies in the serum and the analysis of specific T cells, 
blood was collected from the retro-orbital sinus with a glass capillary pipette. To collect 
serum, 2 drops of blood were collected in an Eppendorf tube and centrifuged at 3500 g for 
10 min. Serum (the supernatant) was carefully taken and stored at -20°C until further 
analysis. For the collection of blood cells, 200 to 300 µl blood were collected in an Eppendorf 
tube containing 50 µl heparin, mixed immediately, and kept on ice. 1 ml of PharmLyse 
ammonium chloride buffer was added to lyse erythrocytes, and samples were incubated for 
10 min at RT before being centrifuged (350 g, 5 min) and washed with PBS to remove 
remaining lysed red blood cells. Cells were then analyzed by flow cytometry. 
3.4.2.2 Spleen cell isolation 
Mice were killed by cervical dislocation and spleens were harvested. Organs were passed 
through a 40 µm cell strainer to get single cell suspensions. Erythrocytes were lysed by 
resuspension of centrifuged cells in red blood cell lysis buffer. Splenocytes were kept in DC 
complete medium for in vitro experiments. 
3.4.2.3 Preparation of bone marrow cells 
Mice were euthanized by cervical dislocation and bone marrow was extracted from femura 
and tibiae by flushing DC medium through the bones and passing the cell suspension 
through a 40 µm cell strainer. Erythrocytes were lysed by resuspension of centrifuged cells in 
PharmLyse ammonium chloride buffer. 
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3.4.2.4 Isolation of lymph node cells 
Mice were killed by cervical dislocation and brachial and axillary lymph nodes were 
harvested. Organs were passed through a 40 µm cell strainer. Single cell suspensions were 
centrifuged and resuspended in DC complete medium. 
3.4.3 Immunization of mice 
3.4.3.1 Dendritic cell immunizations 
To assess the ability of differentially activated DC to elicit antigen-specific cytotoxic T-cell 
responses, naïve C57BL/6 mice were injected with antigen-pulsed DC. For this purpose, FL-
DC were generated, pulsed with ovalbumin protein or peptide antigen and activated with 
6 µg/ml CpG for 4 h or 20 h, as described in chapter 3.2.3 (p. 27). 4 x 105 antigen-pulsed 
activated DC were then injected s.c. together with 100 µg CpG two to three times at 7-day 
intervals. OVA-specific CTL responses were determined one week after the second 
immunization.  
3.4.3.2 Detection of specific immune responses 
Antigen-specific immune responses were detected by analyzing specific serum antibody 
titers, by staining CD8+ T cells with MHC I pentamer complexes, and by examining cytotoxic 
lysis of antigen-loaded target cells. Mice were immunized with the model antigen ovalbumin 
to allow a detailed investigation of antigen-specific responses. 
 
Serum antibody titers were detected by coating ELISA plates with ovalbumin protein. When 
the samples are loaded, specific antibodies bind to the attached protein and can be detected 
by secondary antibodies specific for the heavy chains of murine antibodies that determine 
the isotype of the antibody. By using different antibodies for IgG (all subclasses), IgG1 and 
IgG2a, the respective titers of these antibodies could be detected individually, with IgG2a 
titers being most important as they are indicative of a Th1-type response. The IgG ELISA 
protocol is described in detail in chapter 3.3.1.2, p. 32. 
 
For the detection of antigen-specific cytotoxic T-cells, two assays were used. On the one 
hand, T cells which express a T-cell receptor that recognizes ovalbumin presented in a 
MHC I complex were analyzed by fluorochrome-conjugated complexes of five synthetic 
MHC I molecules, each binding the immunodominant peptide OVA257-264 (SIINFEKL). These 
complexes, also called MHC pentamers, bind to the specific T-cell receptor and allow the 
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assessment of the percentage of cytotoxic T cells specific for ovalbumin by flow cytometry. 
The staining procedure for MHC pentamers is described in chapter 3.3.2.2, p. 34. 
An in vivo cytotoxicity assay was used to examine the cytotoxic function of antigen-specific 
CD8+ T cells. In this assay, peptide-loaded labeled target cells are injected into immunized 
mice and lysis of the target cells is measured in comparison to unloaded cells. Target cells 
were prepared by isolating spleocytes and subsequent red blood cell lysis. The cells were 
divided into two populations and either left unpulsed or pulsed with OVA257-264 peptide 
(10 µg / ml) for 1 h at 37°C. The cells were then w ashed twice with HBSS and each 
population was resuspended in 1 ml HBSS and labeled with a low concentration (1.5 µM) or 
a high concentration (15 µM) of carboxyfluorescein succinimidyl ester (CFSE), respectively. 
Peptide-pulsed CFSEhigh cells and unpulsed CFSElow cells were mixed 1:1 and a total of 
107 target cells were injected i.v. into immunized mice. 3 days later, CFSE-labeled target 
cells from peripheral blood were analyzed by flow cytometry. Specific lysis was calculated as 
follows: 
 
Specific lysis (%) = 100 x [1- (CFSEhigh cells / CFSElow cells) / (CFSEhigh cells in naïve mice / 
CFSElow cells in naïve mice)]. 
3.4.4 C26 tumor experiments 
3.4.4.1 Tumor challenge 
For tumor induction, 2.5 x 105 murine colon carcinoma C26 cells on a Balb/c background 
were injected s.c. into the right flank of Balb/c mice anesthetized with isoflurane. Palpable 
tumors developed from day 5 to 7 onwards. Tumor growth was monitored three times a week 
and expressed as the product of the perpendicular diameters of individual tumors. Animals 
were sacrificed by cervical dislocation when tumor size exceeded 225 mm2. Mice were also 
monitored for signs of distress (see Table 3.1) and were killed when they reached values 
higher than 2 twice in 24 h. Untreated mice had to be killed or died between 20 and 30 days 
after tumor injection, as was already described in earlier studies (Brunner et al., 2000). 
Tumor growth and survival were the readouts of tumor experiments. 
3.4.4.2 Dendritic cell therapy 
For DC therapy, mice received 2 x 105 DC s.c. together with 100 µg CpG in the non tumor-
bearing (contralateral) flank. Prior to injection, immature DC were loaded with UV-irradiated 
tumor cells (0.7 J / cm2) in a ratio of 5:1 24 h before CpG stimulation for 4 or 20 h as 
indicated. In some experiments, mice were additionally injected with 100 µg CpG 
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peritumorally. Treatment was initiated at day 8 to 10 after tumor injection when tumor size 
was 10 to 25 mm2. The interval between the first and second vaccination was 5 days, and 
two more vaccinations were performed at 7-day intervals. Mean tumor size curves of therapy 
groups were plotted until three mice of that group died or were killed. 
3.4.4.3 Rechallenge of mice with tumor cells 
To evaluate long-term protective immunity against tumor antigens, cured mice from previous 
tumor experiments were rechallenged s.c. with 2.5 x 105 C26 tumor cells 99 to 149 days after 
the initial tumor challenge, as indicated. Naïve mice were used as controls. Tumor growth 
was monitored as described above. 
 
Table 3.1: Qualifying pain and distress in rodents (adapted from Morton and Griffiths, 1985). 
Score Degree of distress Physical appearance 
0 None Smooth coat, eyes clear and bright, normal behavior 
1 Minor Piloerection, reduced mobility, normal behavioral 
reactions to external stimuli 
2 Intermediate Rough coat, nasal/ocular discharge, abnormal posture  
(intermittent), depressed provoked behavior 
3 Severe Hunched posture (continuous), respiratory markedly 
increased or reduced, no reaction to external stimuli 
3.4.5 Analysis of in vivo migration of dendritic cells 
Activated DC migrate to draining lymph nodes in order to trigger an antigen-specific immune 
responses by lymphocytes. Migration of DC in vivo was assessed by tracing CFSE-labeled 
DC in the brachial and axillary lymph nodes which were injected in the ventral antebrachium. 
For this purpose, FL-DC were activated with 6 µg/ml CpG for 4 h or 20 h, washed with PBS 
and stained with 3 µM CFSE in PBS for 10 min at 37°C. Cells were washed once in cold PBS 
and once in DC medium, resuspended in PBS and counted. 2 to 4 x 106 cells were injected 
in a volume of 70 µl s.c. in the left forearm of anesthetized mice. 48 h later, mice were killed 
and brachial and axillary lymph nodes were removed from both sides. Lymph node cells 
were gathered and stained with an anti-CD11c antibody to allow the identification of DC 
before cells were analyzed by flow cytometry. 
 
3.5 Statistical analysis 
Statistical analyses were performed by unpaired, one-way analysis of variance (ANOVA) with 
the Newman-Keuls multiple comparison test. Significance was set at P < 0.05. Comparisons 
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in tumor size among groups were made using the Mann-Whitney test for various time points. 
Comparisons among groups regarding survival time were made using the log-rank test. 
Fisher’s exact test was used for comparing tumor incidence in rechallenged mice. Statistical 
analyses were performed using SPSS software. 
 
3.6 Molecular biology methods 
3.6.1 RNA isolation 
To examine which genes are expressed in unstimulated DC and DC after stimulation, total 
RNA was prepared by means of Trizol, a monophasic solution of phenol and guanidine 
isothiocyanate. FL-mDC were magnetically sorted by depletion of B220+ pDC on day 8 of 
FL-DC culture as described in chapter 3.2.4, p. 29. 1.5 to 2 x 106 mDC were stimulated in 
1 ml DC complete medium in Eppendorf tubes with 3 µg/ml CpG, 0.5 µg/ml R848, or were 
left untreated. 4 h later, cells were centrifuged for 5 min at 350 g, supernatants were taken 
and frozen for further analysis by ELISA, and cell pellets were resuspended and lysed in 1 ml 
Trizol. Insoluble material was removed by centrifugation at 12000 g for 10 min, and 
supernatants containing RNA were transferred to new tubes. Homogenized samples were 
incubated for 5 min at RT to permit the complete dissociation of nucleoprotein complexes, 
before 0.2 ml of chloroform were added. Tubes were shaken vigorously by hand for 15 
seconds and then incubated for 3 min at RT before centrifugation at 12000 g for 15 min. The 
colorless upper aqueous phase containing the RNA was then transferred to a fresh tube and 
RNA was precipitated by mixing with 0.5 ml isopropanol and incubating for 10 min at RT prior 
to centrifugation at 12000 g for 10 min. Supernatants were removed and the RNA pellet was 
washed once with 75% ethanol by vortexing, centrifuged again at 7500 g for 5 min, and 
supernatants were removed again. Pellets were left to dry for 1 min at RT and dissolved in 
40 µl H2O. Dissolving was enhanced by heating samples to 55°C for 10 min. RNA 
concentration was measured by Nanodrop photometer. Samples were stored at -80°C for 
further analysis. 
3.6.2 Analysis of gene expression profiles by microarray 
To compare the genes transcribed after CpG and R848 stimulation, we analyzed mRNA 
levels by means of a microarray. Microarrays are two-dimensional arrays, typically on a glass 
or silicon wafer, upon which oligonucleotide sequences are synthesized. These 
oligonucleotides are used as probes to which only the complementary target sequence will 
hybridize. Microarrays are most commonly used for high throughput expression profiling. By 
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hybridizing cDNA or cRNA from specific tissues or cells onto the array, the expression levels 
of thousands of genes can be simultaneously monitored. In this study, cRNA from stimulated 
and unstimulated DC was hybridized to Illumina’s Mouse-6 v1.1 Expression Bead Chips 
which contains probes for 46643 genes covering the whole mouse genome. 
3.6.2.1 Generation and hybridization of cRNA 
Total RNA was isolated from R848- and CpG-stimulated and untreated cells after 4 h 
stimulation as described above. Each condition was done in quadruplicates. RNA was 
reversely transcribed into first strand cDNA with a subsequent synthesis of the second strand 
to obtain a double-stranded template for in vitro transcription with T7 polymerase. During this 
in vitro transcription, biotinylated nucleotides are incorporated to generate labeled cRNA. 
cRNA was prepared using the Illumina TotalPrep RNA Amplification Kit according to the 
manufacturer’s instructions. The purity and quality of total RNA and cRNA was tested by 
capillary electrophoresis in the Agilent Bioanalyzer. Samples were hybridized to two Mouse-
6 v1.1 Expression Bead Chips (Illumina), each containing 6 arrays. To prevent imprecise 
values due to a bias of the different arrays, duplicates of each condition were bound to both 
chips. cRNA synthesis, quality control, and hybridization were done by Peter Weber at the 
Max Planck Institute of Psychiatry in Munich, Germany. 
3.6.2.2 Data readout and analysis 
Microarrays were analyzed using the Beadstation 500. Array scanning and statistical 
evaluation of data was done by Peter Weber and Benno Pütz at the Max Planck Institute of 
Psychiatry, Munich. Quality control of array data was done with Illumina’s scanning software, 
normalization of data was performed by variance stabilization (Huber et al., 2002), and 
differential expression was analyzed by means of the LIMMA package (linear models for 
microarray data, described in Smyth, 2005). Functional analysis of data was perfomed using 
Pathway Studio Software and NCBI’s Entrez Gene database. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Results 
 
Results 
43 
4.1 Kinetics of dendritic cell activation by TLR9 in tumor therapy 
The maturation state of DC is of critical importance for the success of DC tumor vaccines, 
but the most effective mode of maturation is still a matter of debate. In the present study, the 
kinetics of DC activation were analyzed in detail by examining the influence of short-term 
versus long-term activation on DC phenotype and function. DC were differentiated in the 
presence of Flt3L to generate both myeloid and plasmacytoid DC subsets and activated by 
the TLR9 ligand CpG. 
 
4.1.1 Cytokine production 
As a first step, the kinetics of cytokine production by Flt3L-derived DC (FL-DC) after 
stimulation for increasing times with the TLR9 ligand CpG 1826 (CpG) were investigated. 
FL-DC comprise both plasmacytoid and myeloid DC in a relation of approximately 40% pDC 
and 60% mDC. To examine potential differences between pDC and mDC, both populations 
were also separated by magnetic cell sorting and analyzed individually. 
 
DC were stimulated with CpG for 2 h (short-term) up to 24 h (long-term). After the stimulation 
period, cytokine levels were measured in the supernatant (Figure 4.1, grey bars). Cells were 
washed to remove free CpG and culture was continued for a total of 48 h. Cytokine secretion 
after this additional incubation without stimulus indicates the therapeutically relevant fraction 
of cytokines that can be produced in vivo following DC transfer in therapeutic applications 
(Figure 4.1, black bars).  
 
Cytokine production by total FL-DC (Figure 4.1, left column) showed that the bioactive 
heterodimer of IL-12, IL-12p70, was detected as early as 2 h after stimulation with CpG. 
Secretion persisted after removal of the stimulus, so that a 2 h activation period was 
sufficient to induce subsequent IL-12 production, but production ceased after 8 h. IFN-α was 
also produced early, with most of the secretion taking place in the first 8 h after activation. 
The time course of IL-6 secretion showed a sustained production for over 24 h even with 
short activation times. In contrast, IL-10 secretion was initiated late between 12 and 24 h 
after the onset of stimulation, and levels were highest after a stimulation of 24 h. As IL-10 
suppresses the differentiation of Th1 cells, a short stimulation may help to support a Th1-
inducing cytokine milieu. Th1 cells drive cell-mediated immunity in contrast to the humoral 
immunity triggered by Th2 cells.  
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Figure 4.1: Kinetics of cytokine production of FL-DC and sorted pDC. 
Total FL-DC (a mixture of approx. 40% pDC and 60% mDC; left column) and sorted pDC (right 
column) were stimulated with CpG for 2 to 24 h, extensively washed to remove excess CpG and 
cultured without further stimulation for a total of 48 h. Cytokine concentration in the supernatant was 
measured directly after the 2 to 24 h stimulation period (grey bars) and at 48 h, after additional 
incubation without stimulus (black bars). Results show mean and SEM of one representative 
experiment of four. 
 
When analyzing differential cytokine production by the pDC and mDC subpopulations 
isolated from FL-DC, secretion patterns of pDC were similar to that of total FL-DC. pDC are 
the main producers of IFN-α upon TLR stimulation and levels were accordingly high upon 
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activation (Figure 4.1, right column). Cytokine secretion by mDC was also consistent with 
that of total FL-DC, except for IFN-α, which is not produced by mDC upon CpG stimulation 
(Kadowaki et al., 2001 and data not shown).  
 
Thus, activation of total FL-DC for as little as 4 h induces efficient production of all cytokines 
examined. Importantly, the Th1-type cytokines IL-12p70 and IFN-α are produced nearly 
exclusively during the first 8 h after initiation of activation, independently of the duration of 
stimulation. This proposes a higher benefit of remaining cytokine production in vivo when 
using short-term stimulated DC instead of extensively activated, exhausted DC that have 
ceased secretion of IL-12 and IFN-α. 
 
4.1.2 Expression of costimulatory molecules 
To further characterize the potential of short-term CpG-activated DC to initiate T-cell 
responses, we examined the expression of costimulatory and MHC molecules on CpG-
activated DC by flow cytometry. The antigen-specific clonal expansion of naïve T cells 
always requires two signals: on the one hand, the T-cell receptor binds to the appropriate 
peptide - MHC complex on the antigen-specific cell, on the other hand costimulatory 
molecules on the same antigen-presenting cell are needed to avoid the development of 
anergic T cells, that are refractory to activation by specific antigen. The expression of MHC 
and costimulatory molecules therefore reflects the potential of the DC to activate T-cell 
responses. 
 
We analyzed the expression of the costimulatory molecules CD40, CD80, and CD86, and of 
both antigen-presenting complexes, MHC I and MHC II, on FL-DC that were stimulated either 
transiently for 4 h (4h-DC) or long-term for 20 h (20h-DC). For total FL-DC, 4h-DC showed a 
2.5 to 3-fold increase in expression of the costimulatory molecules CD40, CD80 and CD86 
relative to unstimulated DC (Figure 4.2 A and B, first row). Expression of MHC class I and 
MHC class II molecules was also increased. In 20h-DC, costimulatory and MHC molecules 
were further upregulated. In contrast, 48 h after the initiation of stimulation, both 4h-DC and 
20h-DC expressed similar levels of costimulatory and MHC molecules. Expression at 48 h 
was increased compared to unstimulated DC, although to a lesser extent than at earlier time 
points. 
Results 
46 
 
Figure 4.2: Expression of costimulatory and MHC molecules on short- and long-term activated 
DC subsets. 
FL-DC were stimulated with CpG for 4 h (4h-DC) or 20 h (20h-DC), washed to remove excess CpG 
and cultured without further stimulus for a total of 48 h. Surface expression of the indicated markers 
was measured by flow cytometry directly after stimulation and at 48 h. Histograms of total FL-DC (A) 
illustrate the expression of depicted markers on unstimulated cells (dashed line), 4h-DC (grey line) 
and 20h-DC (black line). Graphs (B) show mean fluorescence intensity (MFI) of total FL-DC, mDC and 
pDC (differentiated by FACS analysis) depicted as fold increase relative to unstimulated cells. One 
representative experiment of four is shown. 
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Gating for mDC (CD11c+, CD11bhigh) and pDC (CD11c+, CD11blow) during FACS analysis 
allowed the differentiation of expression levels of costimulatory molecules on mDC and pDC, 
respectively (Figure 4.2 B). Both subsets showed a similar pattern of expression of 
costimulatory and MHC molecules, although the increase of expression levels was more 
pronounced in mDC. 
 
We thus show that short-term stimulation is as efficient as a long-term stimulation to induce 
an activated DC phenotype at 48 h. Furthermore, expression of costimulatory molecules 
decreases after an initial peak, suggesting that the immunostimulatory potential of DC may 
be higher at early time points after activation. 
 
4.1.3 Induction of T helper cell responses 
The early production of the Th1-inducing cytokines IL-12p70 and IFN-α by FL-DC suggested 
that short-term activated DC could be more efficient in the induction of Th1 responses than 
long-term activated DC. Th1 responses are characterized by CD4+ T helper cells that 
produce high amounts of IFN-γ after activation by antigen-presenting cells and that promote 
cell-mediated immunity. Ovalbumin (OVA), the chicken egg albumin, is often used as model 
antigen, as many reagents are available for the detection of OVA-specific immune 
responses. To examine the capacity of FL-DC to generate Th1 responses, OVA protein-
pulsed DC were cocultured for 48 h with OVA-specific CD4 T cells from OT-II mice. T cells 
from these mice bear a transgenic T-cell receptor which recognizes the OVA323-339 peptide in 
the context of a MHC II molecule. After 48 h, the hallmark cytokines for Th1- and Th2-type 
responses, IFN-γ and IL-4, were measured in the supernatants. As predicted, 4h-DC induced 
high levels of IFN-γ, whereas T cells cocultured with 20h-DC produced no more IFN-γ than 
T cells cultured with unstimulated DC (Figure 4.3). No IFN-γ was produced when DC were 
pulsed with a control protein. FL-DC did not promote Th2 responses, as IL-4 was not 
detected in any supernatants (data not shown). 
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Figure 4.3: Induction of Th1 responses by short-term activated FL-DC. 
DC were pulsed with OVA (black bars) or survivin protein as control antigen (white bars), stimulated 
for 4 h or 20 h with CpG and cocultured with sorted OT-II CD4 T cells. IFN-γ production was measured 
in culture supernatants after 48 h. Results show means + SEM of quadruplicates of 2 independent 
experiments (** P < 0.01).  
 
4.1.4 Initiation of cytotoxic T-cell responses 
One of the main goals of DC vaccination is the induction of an efficient cytotoxic T-cell 
response against tumor-associated antigens. To assess the efficiency of short-term activated 
DC to present antigen to CTL, 4h-DC and 20h-DC were pulsed with the MHC I-restricted 
peptide OVA257-264 derived from the OVA protein. Unstimulated DC or DC pulsed with the 
control peptide T1Db derived from the SV40 large T antigen were used as control. DC were 
then cocultured with splenocytes from OT-I mice. T cells from these mice bear a transgenic 
T-cell receptor which recognizes the OVA257-264 peptide in the context of a MHC I molecule. 
In this assay, T-cell proliferation is used as an indicator of DC ability to induce efficient 
cytotoxic T-cell responses. Proliferation of T cells was assessed by a quantitative 
measurement of incorporated BrdU after a 48 h coculture of DC and splenocytes. 
 
Both short- and long-term CpG stimulation enhanced the ability of DC to activate OVA-
specific CD8+ T cell proliferation to a similar extent compared to unstimulated DC (Figure 
4.4 A), when DC were pulsed with OVA peptide. We could not detect a difference between 
short- and long-term activation, showing that a 4 h activation is as effective as an extensive 
stimulation of DC for 20 h.  
 
To initiate a protective CTL response in vivo, extracellular antigens must be taken up, then 
processed and presented in the context of MHC class I molecules by mechanisms termed 
cross-presentation and cross-priming, respectively (Groothuis and Neefjes, 2005). To 
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determine the ability of 4h-DC and 20h-DC to cross-prime antigen-specific T cells, FL-DC 
were pulsed with complete OVA protein before activation with CpG. Antigen-pulsed, 
activated DC were then cocultured with OT-I splenocytes and proliferation was measured 
after 48 h. While unstimulated DC induced little CTL proliferation, activation of DC with CpG 
increased their efficiency to induce CTL proliferation independently of the duration of CpG 
stimulation (Figure 4.4 B).  
 
The effector function of stimulated CTL was analyzed by measuring IFN-γ concentrations in 
the supernatant of DC – OT-I splenocyte cocultures. 4h-DC as well as 20h-DC promoted a 
strong IFN-γ secretion by OT-I CTL, while IFN-γ levels in cocultures with unstimulated DC 
were low. When DC were pulsed with a control peptide, no IFN-γ was induced (Figure 4.4 C), 
confirming the antigen-specificity of the DC-induced T-cell priming. 
 
Thus, 4h-DC induce as efficient a response as 20h-DC when analyzing antigen-specific 
T-cell proliferation in vitro. Short-term activated DC were also highly efficient in cross-priming 
CTL, implying a potent induction of cytotoxic T-cell responses.  
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Figure 4.4: Induction of CTL responses by 4h-DC and 20h-DC. 
(A, B) FL-DC were pulsed with OVA257-264 peptide (A) or ovalbumin protein (B), stimulated for 4 h or 
20 h with CpG and cocultured with splenocytes from OT-I mice. DC-induced T-cell proliferation was 
assessed after 48 h by measuring BrdU incorporation. (C) OT-I splenocytes were cocultured with 
peptide-pulsed DC to induce IFN-γ secretion by CTL. DC were loaded with OVA257-264 peptide (black 
lines) or the irrelevant T1Db peptide as control antigen (dashed lines). One representative experiment 
of three is shown.  
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4.1.5 Inhibition of regulatory T-cell function 
In addition to effector lymphocytes, which are capable of attacking invading microbes, the 
immune system also harbors an inhibitory population of T cells called regulatory T (Treg) cells. 
These cells are specialized in suppressing excessive or misguided immune responses that 
can be harmful to the host, such as responses directed against normal self-constituents 
(Sakaguchi, 2000). On the other hand, overzealous Treg cell responses can impede host 
protective immunity, which plays an important role in the immune evasion of tumors. High 
numbers of Treg cells have been found in lung, pancreas, breast, liver, and skin cancer 
patients, either in peripheral blood or around and within the tumor (Cools et al., 2007). 
However, activation of DC by TLR ligands was shown to overcome the suppression 
mediated by Treg cells (Pasare and Medzhitov, 2003). Due to the importance of Treg cell-
mediated immune suppression in cancer, inhibition of Treg cell function is an essential step for 
the success of any DC vaccination. Therefore we investigated whether short-term activated 
DC can suppress Treg cell function, or if DC need to be activated extensively in order to 
mediate the TLR ligand-induced effects on Treg cells. For these experiments, proliferation of 
CD4+ effector T helper cells was assessed by using an in vitro suppression assay. In this 
assay, CD4+ T helper cell proliferation is induced by cross-linking T-cell receptors with an 
anti-CD3 antibody. When Treg cells are cocultured with anti-CD3-stimulated T helper cells, 
they potently suppress T helper cell proliferation. TLR ligand-stimulated DC can inhibit Treg 
cell-induced suppression and restore T helper cell proliferation, mainly by soluble factors 
such as cytokines (Pasare and Medzhitov, 2003).  
 
To examine the effects of short- and long-term activated DC on Treg cell suppression, 4h-DC 
and 20-DC were added to cocultures of CD4+ T helper cells and Treg cells in the presence of 
anti-CD3 antibody. Proliferation was measured by BrdU incorporation for 12 h after an 
incubation of DC and T cells for 48 h. Cocultures of T helper cells and DC without Treg cells 
were used as control. 
 
While Treg cells suppressed CD4+ T-cell proliferation down to 53 % of initial levels when 
cocultured with unstimulated DC, 4h-DC and 20h-DC restored CD4 T cell proliferation to 
74% and 78% of the levels reached without regulatory T cells, respectively (Figure 4.5 A). In 
Figure 4.5 B, suppression was normalized to levels of cocultures with unstimulated DC. 
These results imply that FL-DC are able to overcome Treg-mediated suppression of T-cell 
proliferation independently of the duration of CpG-activation of the DC. 
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Figure 4.5: Inhibition of regulatory T-cell function. 
4h-DC or 20h-DC were added to a coculture of CD4+ T cells and Treg cells in the presence of anti-CD3 
antibody. Proliferation was measured by chemiluminescent detection of incorporated BrdU. (A) White 
bars show proliferation of T helper cells in the absence of Treg cells, black bars show proliferation of 
T helper cells in coculture with Treg cells. (B) The suppressive effect of Treg cells on T helper cell 
proliferation was calculated by defining Treg cell-mediated suppression in the presence of unstimulated 
control DC as 100% (for exact formula see Materials and Methods, p. 30). Results show means and 
SEM of one representative experiment of three (** P < 0.01, *** P < 0.001, ns not significant). 
 
4.1.6 Migratory capacity of short-term activated dendritic cells 
Upon activation, DC upregulate MHC molecules, CD40, CD80, and CD86, that are required 
for effective interaction with T cells. They also upregulate CCR7, a chemotactic receptor that 
guides DC to lymph nodes, where the DC - T cell interactions take place. 
 
To assess the migratory potential of short- and long-term activated FL-DC, DC were 
analyzed for their expression of CCR7 by flow cytometry. CCR7 expression was rapidly 
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upregulated by CpG activation after 4 h of stimulation and did not further increase when 
stimulation was extended to 20 h (Figure 4.6).  
 
 
Figure 4.6: CCR7 expression of short- and long-term activated DC. 
DC were activated for 4 h or 20 h with CpG and surface expression of CCR7 was measured by flow 
cytometry directly after stimulation. (A) Histograms illustrate the expression of CCR7 on unstimulated 
cells (dashed line), 4h-DC (grey line) and 20h-DC (black line). Graphs (B) show mean fluorescence 
intensity (MFI) of CCR7 expression as mean and SEM of MFI. One representative experiment of three 
is shown (***P < 0.001, ns not significant). 
 
The migratory function of DC was examined in a transwell chemotaxis assay. In these 
assays, migration across a membrane towards the gradient of a chemokine is measured by 
counting the transmigrated cells.  
 
Here, short- and long-term activated DC were analyzed for their capacity to migrate towards 
the CCR7 ligand CCL21 (6Ckine), which is important for DC homing to the lymph node. 
4h-DC as well as 20h-DC migrated very efficiently towards the chemokine gradient 
compared to unstimulated DC, which showed only a poor migration towards the lower 
chamber containing CCL21 (Figure 4.7). Conditions without CCL21 were used as control. 
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Figure 4.7: Migration of 4h-DC and 20h-DC towards the CCR7 ligand CCL21. 
FL-DC were activated for 4 h or 20 h with CpG or left untreated before migration of differentially 
stimulated DC toward CCL21 was assessed in a transwell chemotaxis assay. White bars show 
percentage of migrated cells in conditions without CCL21, black bars illustrate migration of DC when 
CCL21 was added to the lower chamber. Mean and SEM from two experiments are shown 
(***P < 0.001, ns not significant). 
 
4.1.7 In vivo migration to draining lymph nodes 
As a next step, the migratory potential of FL-DC was examined in vivo. For this purpose, DC 
were activated for 4 h or 20 h with CpG or left unstimulated, labeled with CFSE, and injected 
s.c. into the forelimb of naïve mice. 48 h later, the draining (brachial and axillary) lymph 
nodes were harvested and analyzed by flow cytometry. Contralateral lymph nodes were 
excised as control. 
 
Migration of CpG-activated DC to the draining lymph node was increased compared to 
unstimulated DC, although the difference was not significant (P > 0.1). There was no 
difference in the migratory capacity of 4h-DC and 20h-DC (Figure 4.8). Migration only took 
place via the lymphatic vessels as there were no CFSE-positive cells in the contralateral 
lymph nodes or spleen (Figure 4.8 B and data not shown). 
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Figure 4.8: Migration of FL-DC in vivo. 
DC were activated for 4 h or 20 h with CpG or left untreated, labeled with CFSE, and 3 x 106 cells 
were injected s.c. into the left antebrachium of naïve mice. 48 h later, draining (black bars) and 
contralateral (white bars) brachial and axillary lymph nodes were harvested and the percentage of 
CFSE+ cells was analyzed by flow cytometry. (A) Dot plots show representative data of one mouse per 
group. Numbers indicate the percentage of CFSE+ cells in the draining lymph node. (B) Results 
depicted are mean percentages of CFSE+ cells + SEM of 3 mice per group. One representative 
experiment of three is shown.  
 
4.1.8 Immunization with short-term activated dendritic cells 
We demonstrated that short-term activated FL-DC induce antigen-specific IFN-γ secretion by 
Th1 cells and CD8 T-cell proliferation. They can also overcome Treg cell-mediated 
suppression in vitro. To examine the induction of antigen-specific immune responses in vivo, 
naïve C57BL/6 wild-type mice were immunized s.c. with OVA-pulsed FL-DC stimulated with 
CpG for 4 h or 20 h twice at a weekly interval. Serum antibody titers, frequency and cytolytic 
function of CD8+ T cells were examined one week after the last immunization. 
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Serum levels of OVA-specific antibodies were measured to evaluate the effect of vaccination 
with short-term stimulated DC on B-cell responses. Compared to naïve mice, OVA-specific 
total IgG were increased significantly in mice immunized with both OVA protein-pulsed 4h-
DC and 20h-DC (Figure 4.9).  
 
 
Figure 4.9: OVA-specific antibodies after immunization with FL-DC. 
C57BL/6 mice were immunized twice s.c. with 2 x 105 FL-DC pulsed with OVA protein and stimulated 
for 4 h or 20 h with CpG. Concentration of OVA-specific total IgG in serum was measured by ELISA. 
Data show mean values + SEM of three mice per group. Results are representative of two 
independent experiments (***P < 0.001, ns not significant).  
 
In addition to antibody responses, T-cell responses were analyzed after immunization with 
peptide-loaded FL-DC. The focus here was on cytotoxic T-cell responses, as they are crucial 
for the eradication of tumor cells. Synthetic MHC class I pentamers were used to identify 
cytotoxic T cells bearing a T-cell receptor that recognizes the OVA257-264 peptide. Pentamer 
staining of peripheral blood cells showed that immunization with short-term activated FL-DC 
was sufficient to induce a high percentage of OVA-specific CTL, and thus a strong OVA-
specific CTL response (Figure 4.10).  
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Figure 4.10: MHC pentamer staining of OVA-specific CTL. 
C57BL/6 mice were immunized twice s.c. with 2 x 105 FL-DC stimulated for 4 h or 20 h with CpG and 
pulsed with OVA257-264 peptide. Antigen-specific CD8 T cells in peripheral blood were measured by 
flow cytometry with H2-Kb OVA257-264 pentamers one week after the last immunization. (A) Dot plots 
show representative data gated on CD8 T cells. Numbers indicate the percentage of CTL that are 
OVA-pentamer-positive. (B) Graph shows mean and SEM of eight mice from two independent 
experiments (*P < 0.05, ns not significant).  
 
In vivo cytotoxicity assays were done to examine the cytotoxic T-cell response induced by 
vaccination with short- and long-term activated FL-DC. In these assays, peptide-loaded 
labeled target cells were injected into immunized mice and lysis of the target cells was 
measured in comparison to the lysis of unloaded cells, thus allowing an evaluation of the 
cytotoxic function of the antigen-specific CTL. Longer activation of DC for 20 h did not result 
in an increase in the frequency or cytotoxic activity of specific CTL in mice immunized with 
peptide-loaded DC (Figure 4.11 A). Similarly, no increase of cytotoxic activity was seen in 
mice immunized with 20h-DC compared to 4h-DC when DC were pulsed with whole OVA 
protein (Figure 4.11 B). Hence, 4h-activated FL-DC induced an efficient antibody and CTL 
response in vivo that was not increased by longer CpG activation. 
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Figure 4.11: In vivo cytotoxicity of OVA-specific CTL. 
To assess function of CTL, an in vivo cytotoxicity assay was performed by transferring CFSE-labeled 
unpulsed (CFSElow) and peptide-pulsed (CFSEhigh) target cells into immunized mice. Labeled cells 
were detected by flow cytometry in peripheral blood on day 3 after injection. Mice were immunized 
with peptide-pulsed DC (A) or protein-pulsed DC (B). Mean specific lysis and SEM of 5 mice per group 
is shown. Results are representative of two independent experiments (**P < 0.01, ***P < 0.001, ns not 
significant). 
 
4.1.9 Tumor therapy with short-term activated dendritic cells 
To examine whether the CTL response generated by short-term activated FL-DC is able to 
control tumor growth, 4h-DC and 20h-DC were used for DC vaccination in a murine model of 
colon cancer. An immunotherapy protocol combining CpG-activated GM-CSF / IL-4 DC with 
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peritumoral CpG injections to treat established C26 tumors has been established previously 
in our group (Bourquin et al., 2006; Heckelsmiller et al., 2002a). Here, immature FL-DC were 
pulsed with UV-irradiated tumor cells, acti-vated in vitro with CpG, and injected together with 
100 µg CpG on the flank opposite the tumor. In some treatment groups, an additional dose of 
100 µg CpG was injected in the peritumoral area to enhance the immunostimulatory effect.  
 
 
Figure 4.12: Tumor therapy with short-term activated FL-DC. 
Balb/c mice bearing palpable C26 tumors were injected s.c. with 100 µg CpG and CpG-activated 
FL-DC pulsed with irradiated tumor cells in the flank opposite the tumor. Two groups received an 
additional 100 µg CpG peritumorally. The treatment was administered four times at 5- to 7-day 
intervals (arrows). (A) 4h-DC and 20h-DC significantly reduced tumor growth compared to untreated 
mice (*P < 0.05 from day 18 onwards). The addition of peritumoral CpG led to complete tumor 
regression in all treated mice (**P < 0.01 compared to untreated mice at all time points from day 13). 
Mean tumor size of treatment groups (n=5) is plotted until two mice per group remain. (B) Treatment 
with either 4h-DC or 20h-DC significantly increased survival (P < 0.01). Similar results were obtained 
in four independent experiments. 
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Antigen-pulsed, activated FL-DC injected together with 100 µg CpG on the contralateral flank 
reduced tumor growth and led to a significant increase in survival compared to untreated 
mice (Figure 4.12). This therapeutic effect was independent of the duration of the in vitro 
activation of the DC. When the therapy was supported with an additional injection of CpG in 
the peritumoral area, all mice rejected their tumors and remained tumor-free for four months 
after the last DC vaccination. It was previously shown that using this protocol, peritumoral 
CpG injection alone does not result in a significant reduction of tumor growth (Heckelsmiller 
et al., 2002a). In addition, immunization with irradiated tumor cells and CpG in the absence 
of DC did not protect against a subsequent tumor challenge and could not cure established 
C26 tumors (Heckelsmiller et al., 2002b). 
 
To evaluate long-term protection, the cured mice were rechallenged s.c. with C26 tumor cells 
four months after the last treatment. Naïve mice were used as controls. None of the cured 
mice developed a tumor. In contrast, all naïve control mice developed tumors (Table 4.1, 
P = 0.008). There was no difference between mice treated with 4h-DC or 20h-DC. Thus, 
short-term activated DC effectively cured established tumors and at the same time induced a 
potent memory response that provided protection until after several months after the last 
treatment.  
 
Table 4.1: Tumor formation in mice cured from C26 tumors and rechallenged with C26 cells. 
 naïve 4h-DC + CpG 20h-DC + CpG 
Proportion of mice 
with tumor 
5 of 5 0 of 5 0 of 5 
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4.2 Distinctive features of TLR7 stimulation 
CpG as a TLR9 ligand enhances immune responses in many murine tumor models and has 
shown substantial evidence of antitumor activity in human clinical trials (Krieg, 2007). 
However, the distribution of TLR9 differs substantially between murine and human DC 
populations. In mice, TLR9 is expressed by pDC and mDC, whereas in humans TLR9 
expression is mainly restricted to pDC (Krug et al., 2001). Similarly to TLR9, DC can also be 
stimulated via TLR7 and TLR8, which are expressed on both human and murine mDC and 
pDC (Hornung et al., 2002) and ligands of TLR7/8 have already been successfully used as 
vaccine adjuvants in clinical trials (Shackleton et al., 2004). TLR7/8 and TLR9 are described 
to activate the same intracellular pathways via MyD88. In view of the therapeutic potential of 
TLR7 ligands, their influence on DC maturation was analyzed in closer detail. 
 
4.2.1 Kinetics of TLR7-induced cytokine production  
As analyzed in chapter 4.1.1 for TLR9 stimulation with CpG, the kinetics of FL-DC activation 
were examined for ligands of TLR7 and 8. The experimental setup was identical to the 
stimulation with CpG: Total FL-DC were stimulated with R848 as ligand for murine TLR7 
(and TLR8 in humans), or CL087 as a pure TLR7 ligand, for 2 h up to 24 h. After the 
stimulation period, cytokine levels were measured in the supernatant (Figure 4.13, grey 
bars). Cells were washed and culture was continued for a total of 48 h, when again cytokine 
secretion was determined (Figure 4.13, black bars).  
 
For both ligands, IL-12p70 secretion through TLR7 was induced even more rapidly than with 
the TLR9 ligand CpG and persisted after removal of the stimulus (Figure 4.13). As with CpG 
stimulation, production ceased after 6 h. IL-6 showed a sustained secretion for over 24 h. 
IL-10 was again secreted late, and levels were highest after long stimulation times. Thus, as 
for TLR9, TLR7/8 activation induces rapid and efficient production of Th1 cytokines by DC 
that is restricted to the first 6 to 8 hours after initiation of stimulation. 
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Figure 4.13: Kinetics of cytokine production of FL-DC after TLR7 stimulation. 
Total FL-DC were stimulated with the TLR7/8 ligand R848 or CL087 as TLR7 ligand for 2 to 24 h, 
extensively washed to remove excess ligands and cultured without further stimulation for a total of 
48 h. Cytokine concentration in the supernatant was measured directly after the 2 to 24 h stimulation 
period (grey bars) and at 48 h, after additional incubation without stimulus (black bars). Results show 
mean and SEM of one representative experiment of three.  
 
4.2.2 Lack of IL-12p70 production in TLR7-activated dendritic cells 
Interestingly, cytokine secretion differed substantially between DC subsets after stimulation 
with the TLR7/8 ligand R848. When FL-DC were magnetically sorted into B220+ pDC and 
B220- mDC, mDC produced IL-12p70 only upon TLR9 but not TLR7 activation. Yet, pDC as 
well as mDC generated by conventional GM-CSF / IL-4 culture responded to both CpG and 
R848 with a similar production of IL-12p70 (Figure 4.14 A). FL-mDC did secrete other 
cytokines including the IL-12p40 subunit upon R848 stimulation, indicating the expression of 
functional TLR7 receptors on these cells (Figure 4.14 B). Stimulation by other TLR7 and 
TLR7/8 ligands, such as Imiquimod, Gardiquimod, CL079, CL087, and CL097 showed the 
same pattern of cytokine production (data not shown). This discrepancy between TLR7- and 
TLR9-induced IL-12 secretion is likely to be a general feature FL-mDC, as it was seen in 
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cells from mice with different genetic backgrounds (Balb/c and C57BL/6, data not shown). As 
TLR7 and TLR9 are thought to activate the same intracellular signaling pathways, we 
decided to further analyze this difference.  
 
 
Figure 4.14: Cytokine production by DC subsets upon R848 stimulation. 
Total FL-DC and sorted pDC and mDC of the FL-DC culture as well as mDC generated by culture with 
GM-CSF and IL-4 were stimulated with R848 (black bars), CpG (grey bars), or left untreated (white 
bars) for 20 h and cytokine concentration in the supernatant was measured by ELISA. Results show 
mean and SEM of one representative experiment of five. 
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4.2.3 The role of p38 MAPK for IL-12p70 inhibition 
The molecular mechanisms underlying the IL-12 production by DC are not fully understood, 
although different molecules have been identified that play a role in its regulation. The family 
of mitogen-activated protein kinases (MAPK) has been implicated in the regulation of IL-12 
by different authors, and especially the p38 MAPK was shown to control transcription of both 
the p40 and the p35 subunit of the bioactive IL-12p70 heterodimer (Lu et al., 1999). Further, 
inhibition of p38 MAPK by the pyridinyl imidazole inhibitor SB203580 reduced the amounts of 
IL-12p70 secreted upon LPS stimulation or CD40 ligation in bone-marrow derived DC 
generated with GM-CSF and an immature murine splenic DC cell line (Fukao et al., 2002; 
Kikuchi et al., 2003; Yanagawa and Onoe, 2006). To examine whether TLR7-induced IL-12 
production was influenced by p38 MAPK, IL-12p70 secretion of R848-stimulated FL-DC 
subsets was examined in the absence and presence of the p38 MAPK inhibitor SB203580.  
 
FL-mDC, which do not secrete IL-12p70 production upon TRL7 stimulation without p38 
MAPK inhibition, showed a marked increase of IL-12p70 secretion when p38 MAPK was 
blocked by SB203580. In contrast, IL-12p70 production in pDC was inhibited (Figure 4.15). 
Thus, pDC react to p38 MAPK inhibition similarly as described for LPS-stimulated GM-CSF 
DC, whereas FL-mDC seem to rely on a different regulation of IL-12 production that is 
inhibited by p38 MAPK.  
 
 
Figure 4.15: IL-12p70 secretion after inhibition of p38. 
mDC and pDC sorted from FL-DC were incubated with different concentrations of the p38 inhibitor 
SB203580 for 30 min before cells were stimulated with R848 or left unstimulated for 20 h. IL-12p70 
concentration in the supernatant was measured by ELISA. Results show mean and SEM of triplicate 
wells. 
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4.2.4 Influence of various cytokines on IL-12p70 secretion 
To further characterize the regulation of IL-12p70 production in FL-mDC, cells from mice 
deficient for different signaling molecules were analyzed. IL-10 has been known to negatively 
regulate the secretion of IL-12 for more than 15 years (D'Andrea et al., 1993). The NF-κB 
family member p50 was proposed to induce the transcription of IL-10 (Cao et al., 2006), and 
heterodimers of p50 and other NF-κB transcription factors like p65 and c-Rel were described 
to contribute to the transcription of many inflammatory cytokines, including IL-12 (Doyle and 
O'Neill, 2006). Transcription factors of the IRF family on the other hand are responsible for 
the induction of interferons. As especially type I interferons have been shown to promote 
IL-12 production via an autocrine-paracrine feedback loop (Gautier et al., 2005), knock-out 
mice that lack both IRF3 and IRF7 were also examined. 
 
FL-DC were generated from bone marrow cells from wild-type C57BL/6 mice and mice 
deficient for either IL-10, p50, or both IRF3 and IRF7. Sorted mDC were stimulated with 
R848 or CpG as positive control, and supernatants were analyzed for IL-12p70 
concentrations. 
 
 
Figure 4.16: IL-12p70 production in different knock-out mice. 
mDC from different mouse strains were sorted by B220 depletion from FL-DC and stimulated with 
R848 (black bars) or CpG (grey bars) for 20 h. IL-12p70 concentration in the supernatant was 
measured by ELISA. Results show mean and SEM of one representative experiment of two. wt wild-
type, -/- homozygous knock-out. 
 
As expected, IL-12p70 secretion was higher in cells from IL-10 knock-out mice than in wild-
type cells, confirming the negative regulation of IL-12 by IL-10 (Figure 4.16). Yet, while IL-12 
production after CpG was increased only by about 30%, IL-12 concentration in R848-
stimulated cells was induced much more potently than in wild-type cells with levels that were 
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almost 15-fold increased compared to wild-type cells. IL-12p70 secretion was reduced but 
still existent in both p50- and IRF3/7-deficient cells (Figure 4.16), indicating an important but 
not exclusive role for these transcription factors in the induction of IL-12. While IRF3/7 knock-
out cells showed the same pattern as wild-type cells with no IL-12p70 secretion upon R848 
stimulation, p50-deficient cells produced low amounts of IL-12 after TLR7 stimulation. This is 
probably due to the reduced IL-10 levels in these cultures (Cao et al., 2006) and therefore 
mimics the results of the IL-10 knock-out cells. 
 
Thus, IL-10 seems to be important for the inhibition of IL-12p70 production upon R848 
stimulation. Yet, CpG induces even higher levels of IL-10 secretion in wild-type FL-mDC than 
TLR7 activation by R848 (Figure 4.17), indicating an additional or different regulatory 
mechanism underlying the lack of IL-12p70 production after TLR7 stimulation. The delayed 
kinetics of IL-10 secretion compared to IL-12p70 production (see Figure 4.13, p. 62) further 
support the necessity of another regulatory factor controlling IL-12 secretion in FL-mDC. 
 
 
Figure 4.17: IL-10 production by FL-mDC. 
Magnetically sorted FL-mDC from wild-type mice were stimulated with R848, CpG, or left untreated for 
20 h and IL-12p70 concentration in the supernatant was measured by ELISA. Results show mean and 
SEM of one representative experiment of three. 
 
4.2.5 Gene expression profiles of TLR7- versus TLR9-stimulated FL-mDC 
To further examine the regulation of IL-12 production in FL-mDC, we analyzed genome-wide 
expression profiles of FL-mDC stimulated with R848 and CpG by means of a microarray. 
FL-mDC were magnetically sorted by depletion of B220+ pDC from total FL-DC from wild-
type C57BL/6 mice and examined by FACS analysis for their purity. Cells were stimulated 
with R848 or CpG for 4 h or left untreated before RNA was isolated. A short 4 h stimulation 
period was chosen because of the rapid induction of IL-12p70 and because of possible 
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indirect effects of other newly induced genes that would bias the results. cRNA was prepared 
and hybridized to two Illumina Mouse-6 v1.1 Expression Bead Chips as described in chapter 
3.6.2.1, p. 40. Hybridization, scanning and statistical analysis of the microarrays were done 
by Peter Weber and Benno Pütz at the Max Planck Institute of Psychiatry in Munich, 
Germany. Cytokine concentration in the supernatants was analyzed by ELISA to test for a 
successful stimulation and showed the induction of IL-6 in all R848- and CpG-stimulated 
samples and the production of IL-12p70 by CpG-stimulated samples, as expected (data not 
shown). 
Microarray data was normalized and further submitted to a cluster analysis to visualize 
similarities between the expression profiles of the different samples. As shown in the 
dendrogram in Figure 4.18, the quadruplicates of each condition are clearly separated into 
distinct branches, implying a good reproducibility of results despite the distribution of the 
samples on two different arrays. It also shows that the expression profiles of R848- and CpG-
stimulated cells are more similar to one another than to those of unstimulated cells, indicating 
the induction of similar gene transcription networks in both TLR7- and TLR9-stimulated cells. 
  
 
Figure 4.18: Clustering of normalized data. 
Cluster analysis of normalized microarray data visualizes similarities between the expression profiles 
of different samples. A unstimulated cells, B R848 stimulated cells, C CpG stimulated cells, 1-4 
number of quadruplicates. 
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For further analysis, differentially expressed genes were identified by comparing gene 
expression levels between the different samples. The evaluation of all conditions as a 
combined contrast was done by ANOVA; for single contrast analysis, Student’s t-test was 
used. 4603 genes showed no expression signals in any sample and were excluded from 
subsequent analysis. Due to the high number of differentially expressed genes, the level of 
significance was set at P < 0.001. Table 4.2 gives an overview of the number of regulated 
genes determined by t-test. 
 
Table 4.2: Differentially expressed genes in microarray experiment (P < 0.001). 
 
Total Down Up 
R848 vs unstim 3367 1721 1646 
CpG vs unstim 5749 3313 2436 
R848 vs CpG 1375 681 694 
Down downregulated , Up upregulated. 
 
To examine the distinctive mechanism of TLR7 and TLR9 stimulation, pathways or regulatory 
genes were sought that are only expressed with either TLR7 or TLR9 stimulation. For this 
purpose, genes that were differentially expressed in R848-stimulated cells compared to 
unstimulated cells were matched with genes that were either up- or downregulated in CpG-
stimulated cells compared to unstimulated cells. Due to the high number of differentially 
expressed genes in both conditions, the cutoff for further analysis was set more stringently: 
Differentially expressed genes were sorted by their respective fold change in expression. For 
R848 versus unstimulated, genes with a fold change of more than 2, for CpG versus 
unstimulated, genes with a fold change of more than 2.5 were chosen for further analysis, 
yielding approximately 1000 genes in each condition. Differentially expressed genes in CpG-
stimulated cells were computationally subtracted from those genes that were regulated after 
R848 stimulation and vice versa. These genes were manually matched up reciprocally. For 
this purpose, fold changes in expression levels of stimulated cells versus unstimulated cells 
were compared between CpG and R848 stimulation. For R848-stimulated samples, only 
genes with a fold change differing by more than 1.5 to the fold change induced by CpG 
stimulation were selected, yielding 15 genes that were stimulated after R848 but not CpG 
stimulation. 4 of these genes play a role in inflammatory responses, and 3 are described to 
act in signal transduction (Table 4.3). For CpG-stimulated samples, the required difference in 
fold changes was set to 2.5, resulting in 46 genes. Here, 8 and 13 genes are responsible for 
inflammatory responses and signaling, respectively (Table 4.4). Expression levels of these 
genes will be verified by quantitative real-time PCR.  
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Table 4.3: Genes differentially expressed after R848 but not CpG stimulation. 
Gene Biological process Fold change R848 vs unstim 
Fold change 
CpG vs unstim 
Difference 
R848 vs CpG 
(ranking value) 
CSF3 Inflammatory response 6.2 n.s. 6.2 
IL21R Inflammatory response 2.1 -1.5 3.6 
ORM1 Inflammatory response 2.9 n.s. 2.9 
FCGR1A Inflammatory response 3.1 1.3 1.8 
GPR35 Signaling 2.1 -1.7 3.8 
SDCBP2 Signaling 2.0 n.s. 2.0 
JAK3 Signaling 2.0 n.s. 2.0 
PIWIL2 Other 3.2 -1.5 4.7 
KIAA0062 Other 2.1 -1.3 3.4 
IER3 Other 2.4 n.s. 2.4 
CCND1 Other 2.2 n.s. 2.2 
SIAT9 Other -2.1 n.s. 2.1 
DNMT3L Other 2.0 n.s. 2.0 
retnlg Unknown -4.3 -1.7 2.6 
CRA Unknown 2.1 n.s. 2.1 
 
 
Table 4.4: Genes differentially expressed after CpG but not R848 stimulation. 
Gene Biological process Fold change CpG vs unstim 
Fold change 
R848 vs unstim 
Difference 
CpG vs R848 
(ranking value) 
igh-1a Inflammatory response 8.9 n.s. 8.9 
LTA Inflammatory response 10.2 1.7 8.5 
FCGRT Inflammatory response -7.1 -1.6 5.5 
TZFP Inflammatory response 7.0 1.7 5.2 
IL6ST Inflammatory response -4.2 n.s. 4.2 
TNFSF15 Inflammatory response 3.6 n.s. 3.6 
IFNB1 Inflammatory response 3.2 n.s. 3.2 
CD8B1 Inflammatory response 4.9 2.0 2.9 
PLEKHG2 Signaling -2.7 1.6 4.3 
MYLK Signaling 4.1 n.s. 4.1 
Tim2 Signaling 4.0 n.s. 4.0 
EDG7 Signaling -2.5 1.4 3.9 
CREM Signaling -3.9 n.s. 3.9 
GPR146 Signaling -3.6 n.s. 3.6 
CD19 Signaling 4.8 1.8 3.0 
DLL4 Signaling 2.9 n.s. 2.9 
NR4A2 Signaling -2.9 n.s. 2.9 
ARHE Signaling 2.8 n.s. 2.8 
PLXNB2 Signaling -2.7 n.s. 2.7 
WNT11 Signaling -2.7 n.s. 2.7 
TCF7L2 Signaling 3.9 1.3 2.6 
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Gene Biological process Fold change CpG vs unstim 
Fold change 
R848 vs unstim 
Difference 
CpG vs R848 
(ranking value) 
HIP1 Other -3.8 1.5 5.3 
ITGA3 Other -6.6 -1.8 4.9 
HS3ST1 Other 4.5 n.s. 4.5 
CACNA1S Other 4.6 1.3 3.3 
TPBG Other 3.3 n.s. 3.3 
OLFM1 Other -4.5 -1.4 3.1 
GFI1B Other 4.9 1.8 3.1 
FLJ20559 Other 4.6 1.6 3.1 
ITGB8 Other 4.6 1.8 2.9 
CKIP-1 Other -4.4 -1.6 2.8 
MAP1B Other -2.7 n.s. 2.7 
TOSO Other 2.7 n.s. 2.7 
BMF Other -2.6 n.s. 2.6 
RBPMS Other 4.4 1.9 2.6 
ST14 Other 2.5 n.s. 2.5 
dhrs8 Other 4.1 1.7 2.5 
au044919 Unknown 5.7 1.3 4.4 
C10orf81 Unknown 4.0 n.s. 4.0 
Phxr4 Unknown 5.4 1.8 3.6 
RHBDL3 Unknown 3.6 n.s. 3.6 
C1orf161 Unknown 3.0 n.s. 3.0 
WDR59 Unknown 2.7 n.s. 2.7 
KRT222P Unknown 2.5 n.s. 2.5 
TLCD1 Unknown 4.0 1.5 2.5 
C18orf17 Unknown 4.2 1.8 2.5 
 
Protein names in italics show genes that are represented on the array with more than one probe but 
showed similar results with all probes. 
 
Expression data confirmed cytokine production from previous experiments, with high levels 
of IL-12p35 transcripts only after CpG but not R848 stimulation (Figure 4.19). The increase of 
RNA levels of the p40 subunit was also higher in CpG- than in R848- stimulated cells, 
reflecting p40 concentrations in supernatants. Expression of IL-10 was upregulated with 
TLR7 as well as TLR9 stimulation and confirmed previous data. Expression of MAPK14 
(p38α), the only isoform of p38 MAPK which showed transcriptional regulation in this assay, 
was downregulated with both stimulations (Figure 4.19). 
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Figure 4.19: Expression of candidate genes in microarray. 
Expression levels of IL-12p35, IL-12p40, IL-10 and MAPK14 (p38α) were compared between 
unstimulated cells and R848- and CpG-stimulated cells, respectively. Different RNA levels are shown 
as fold change in stimulated cells versus unstimulated cells. ns not significant.  
 
4.2.6 Integrating data by pathway analysis 
To further evaluate the biological pathways responsible for IL-12p35 transcription, 
differentially expressed genes were analyzed by pathway analysis using the Pathway Studio 
Software. When the genes that were only regulated with either TLR7 or TLR9 stimulation 
were examined for connective pathways by literature information embedded in the Pathway 
Studio software, no signaling network was identified.  
 
By integrating gene expression levels from the present study with described regulators of 
IL-12 transcription, only IL-10, IFN-γ, and IRF1 showed higher expression levels after 
stimulation. Since these genes were all upregulated with TLR7 as well as TLR9 stimulation, 
they are probably not responsible for the differences in IL-12p35 transcription described 
above. 
 
As a next step, common regulators for IL-10 and IL-12 were analyzed for their expression 
levels in the microarray experiment. Figure 4.20 shows genes described to regulate both 
IL-10 and IL-12 synthesis that were differentially expressed in stimulated compared to 
unstimulated cells. Expression levels after R848- and CpG stimulation were similar for all 
genes but IFN-β1, which was found to be regulated only with CpG but not R848 stimulation. 
Further analysis is necessary to examine the importance of IFN-β production for IL-12p70 
secretion and additional mechanisms regulating IL-12 production after TLR7 and TLR9 
stimulation.  
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Figure 4.20: Expression pattern of common regulators of IL-12 and IL-10 transcription after 
TLR7 and TLR9 stimulation. 
Genes described to regulate production of IL-12 and IL-10 were analyzed for their expression in the 
microarray experiment. Only genes that were differentially expressed after TLR stimulation are shown. 
Red symbols indicate genes that were upregulated, green symbols indicate genes that were 
downregulated by both R848 and CpG stimulation (compared to unstimulated cells). Expression of 
IFN-β1 (IFNB1) and IL-12p35 was only upregulated after CpG but not R848 stimulation (shown as 
dark red). 
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5.1 Kinetics of dendritic cell activation in tumor therapy 
Dendritic cells are able to initiate T-cell responses, induce immunological memory and break 
immunological tolerance to tumors. Their ability to stimulate cytotoxic T cells and to polarize 
T helper cells towards a Th1 profile makes them promising elements of cancer 
immunotherapy (Tuyaerts et al., 2007). Nevertheless, DC-based vaccines have so far failed 
to meet expectations in clinical settings (Zhong et al., 2007). Several questions remain to be 
resolved in order to improve the efficacy of DC vaccines, such as the development of 
effective strategies for DC maturation and the appropriate usage of DC subtypes. 
 
5.1.1 Advantages of Flt3L-generated dendritic cells for immunotherapy 
DC subsets represent a complex immunological system distributed in different 
microenvironments within the body. They also sense different types of pathogens and 
modulate different classes of immune responses (Pulendran et al., 2008). Nevertheless, 
recent work suggests several mechanisms of crosstalk between the different DC subsets. 
Langerhans or dermal DC have been reported to interact with CD8+ lymph node DC in the 
cross-presentation of s.c. injected antigens (Allan et al., 2003; Lund et al., 2003), whereas 
pDC cooperate with lymph-node mDC to generate antiviral CTL in herpes simplex virus 
infection (Yoneyama et al., 2005). In murine L. monocytogenes infections, IL-15-dependent 
crosstalk between mDC and pDC was necessary for CpG-induced immune activation 
(Kuwajima et al., 2006). A better understanding of the functional heterogeneity of DC subsets 
and their interactions is required to optimize the use of different subsets in immunotherapy. 
Currently, most clinical trials use the single subset of monocyte-derived mDC (Proudfoot et 
al., 2007). However, the most successful immunotherapeutic strategies will likely be those 
that maintain the diversity of DC subsets. The ability of the hematopoietic growth factor Flt3L 
to expand the number of DC in vitro and in vivo offers an alternative strategy that allows the 
generation of a diverse repertoire of DC subsets (Maraskovsky et al., 1996; Maraskovsky et 
al., 2000). Flt3L also regulates DC development in vivo as it was shown that Flt3L-deficient 
mice have reduced DC numbers (McKenna et al., 2000), injection of mice with Flt3L greatly 
induces DC numbers (O'Keeffe et al., 2002), and that only bone-marrow progenitor cells 
expressing Flt3 are effective precursors of DC (D'Amico and Wu, 2003). In the present study, 
we have differentiated DC in the presence of Flt3L in order to generate both myeloid and 
plasmacytoid DC (Brasel et al., 2000). pDC represent key effector cells in both innate and 
adaptive immunity due to their efficient production of type I interferons upon stimulation (Ito 
et al., 2004). Lou et al. could show that pDC alone are able to stimulate antigen-specific 
immune responses in a murine tumor model, but that the combination of pDC and mDC 
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promotes the strongest CTL responses (Lou et al., 2007). We show that the combination of 
short-term activated myeloid and plasmacytoid DC is effective for the immunotherapy of 
established tumors. Several experiments in our laboratory compared the effectivity of 
GM-CSF- plus IL-4-generated mDC with FL-DC. FL-DC were always superior in eliciting 
antitumor responses, which also underlines the importance of a crosstalk between the 
different DC subsets (data not shown). Due to these promising results in murine models, DC-
based cancer vaccines should be optimized by using the interplay between multiple cell 
types which can be achieved by generating DC with Flt3L. 
 
5.1.2 The difficult choice of the right stimulus 
Maturation and activation of DC are essential in order to elicit the protective T-cell responses 
required for tumor immunotherapy. Activated DC produce proinflammatory cytokines, 
upregulate surface expression of MHC and costimulatory molecules and migrate from 
peripheral tissues to lymph nodes. There, DC present antigen to T cells in order to initiate an 
antigen-specific immune response. In contrast, immature splenic DC are tolerogenic in the 
steady-state, taking up antigen from the environment, and presenting it to T cells in the 
absence of a costimulatory signal, thereby inducing a tolerogenic outcome (Hubert et al., 
2007). A growing body of evidence now indicates that immature DC can also actively 
maintain peripheral T-cell tolerance by the induction of regulatory T cells (Belz et al., 2002; 
Jonuleit et al., 2000). This induction of suppressive T cells has also been shown in vivo in 
humans, where antigen-bearing immature DC induced peptide-specific CD8+ regulatory 
T cells (Dhodapkar and Steinman, 2002). Two clinical studies compared the effects of 
immature and mature DC on tumor immune responses directly: In melanoma patients, 
mature DC were superior in eliciting T-cell responses, which resulted in objective clinical 
responses in two patients (de Vries et al., 2003; Jonuleit et al., 2001).  
 
Many signals have been shown to induce at least some aspects of DC activation. In the 
majority of published clinical trials to date, DC are matured with a cytokine cocktail consisting 
of TNF, IL-1β, IL-6 and prostaglandin E2 (PGE2), first described by Jonuleit et al., 1997. This 
protocol induces a mature DC phenotype with upregulation of costimulatory molecules that 
supports clonal expansion of CD4+ T cells. However, recent findings show that DC that have 
been activated by inflammatory mediators are poor producers of IL-12p70 and thus do not 
promote T-cell differentiation towards a Th1 phenotype in vivo (Lee et al., 2002; Sporri and 
Reis e Sousa, 2005). Furthermore, cytokine-activated DC, which are sometimes 
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characterized as “semi-mature”, have been shown to induce immunosuppressive regulatory 
T cells (Lutz and Schuler, 2002; Menges et al., 2002).  
 
In contrast, TLR ligands induce the complete activation of DC: On the one hand, they control 
the expression of many innate immune response genes and can directly promote DC 
activation. On the other hand, signaling from these receptors leads to the synthesis of 
inflammatory cytokines such as IFN-α or IFN-β, TNF, and IL-1, all of which can also trigger 
DC activation indirectly (Sporri and Reis e Sousa, 2005; Winzler et al., 1997). In addition, 
TLR signaling promotes the synthesis of other inflammatory mediators such as chemokines, 
prostaglandins and leukotrienes, which can also lead to DC activation (Reis e Sousa, 2004). 
DC activated by agonists of TLRs induce efficient Th1 responses both in vitro and in vivo and 
lead to the efficient generation of cytotoxic T cells (Iwasaki and Medzhitov, 2004; Krieg, 
2007). In the present study, we show that antigen-pulsed CpG-activated DC were able to 
induce strong Th1 and CTL responses that led to the eradication of established tumors. DC 
activated by TLR ligands may therefore provide more effective antitumoral immunity in 
clinical trials. Indeed, maturation of human DC with a combination of the TLR3 ligand poly I:C 
and inflammatory cytokines induced more potent CTL responses in vitro than the classical 
cytokine cocktail (Mailliard et al., 2004). 
 
To date, the TLR9 ligand CpG has been identified as the most potent immune enhancer in 
mouse tumor models (Krieg, 2007). However, TLR9 expression in humans is mainly 
restricted to plasmacytoid DC (Krug et al., 2001). Nevertheless, CpG has to date shown 
substantial evidence of antitumor activity in human clinical trials (Krieg, 2007). DC can also 
be stimulated via TLR7 and 8 and ligands of TLR7 and 8 have already been successfully 
used as vaccine adjuvants in clinical trials (Shackleton et al., 2004). In the future, specific 
RNA oligonucleotides may also prove suitable for tumor therapy, as immunostimulatory RNA 
oligonucleotides induce potent T-cell responses in mice and activate both myeloid and 
plasmacytoid human DC through TLR7 (Bourquin et al., 2007; Heil et al., 2004). 
Furthermore, the combination of ligands for different TLRs can lead to potent synergy for the 
induction of IL-12 and Th1-polarization by DC in both mice and men (Napolitani et al., 2005; 
Warger et al., 2006). 
 
5.1.3 The danger of “exhausting” dendritic cells 
Although the importance of DC maturation for tumor immunotherapy is now widely accepted, 
the timing of DC activation remains to be investigated in detail. In most clinical trials, 
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maturation protocols require extensive in vitro activation of DC for 48 h. However, it has been 
shown that this long activation time leads to a cutback of cytokine production, in particular for 
the key Th1-polarizing cytokine IL-12p70. This phenomenon, termed DC exhaustion, occurs 
independently of the stimulus used for maturation and is associated with the absence of DC 
response to further stimulation both in vitro and in vivo (Kalinski et al., 1999; Langenkamp et 
al., 2000; Reis e Sousa et al., 1999). Since excess IL-12 can lead to lethal tissue damage, its 
production must be tightly regulated. IL-10, which is usually synthesized together with IL-12, 
plays a major role in protecting the host from permanent damage by downregulating IL-12 
expression (Berg et al., 1995). Although DC exhaustion is beneficial in regulating immune 
responses in inflammation and infection, it may prove to be deleterious when exhausted DC 
are injected as a tumor vaccine, where IL-12 secretion is needed for the induction of Th1 and 
CTL responses. Short activation times could possibly prevent DC exhaustion, but little is 
known about the type of immune response induced in vivo by DC activated through short 
TLR stimulation (Macagno et al., 2007). 
 
In the present study, short activation of DC for 4 hours by the TLR9 ligand CpG triggered a 
complete maturation program including the rapid production of Th1-type cytokines, 
upregulation of costimulatory molecules, migration towards a CCR7 ligand and efficient 
antigen presentation to CTL. Importantly, the Th1-polarizing cytokines IL-12p70 and IFN-α 
were produced only in the early phase following DC stimulation, leading to a more efficient 
induction of IFN-γ-producing Th1 cells by short-term activated DC. Taken together, these 
results suggest that vaccination with short-term activated DC may ensure the benefit of fully 
mature migratory DC that still produce high levels of Th1 cytokines and may thus emerge 
superior to extensively matured DC in tumor vaccines. 
 
5.1.4 Duration and combination: signal integration in dendritic cells 
In a physiological context, DC are exposed sequentially to different stimuli: microbial 
products and inflammatory cytokines are encountered initially in peripheral tissues, whereas 
T cell-derived signals such as CD40 – CD40L interaction and binding of the T-cell receptor to 
the peptide-MHC complex are delivered when DC have reached the T-cell areas of 
secondary lymphoid organs. The importance of sustained receptor stimulation in the context 
of T-cell activation is widely acknowledged. The signaling process is described to be 
sustained by sequential engagements of T-cell receptors, which are serially triggered by low 
affinity peptide-MHC complexes. Blocking of the T-cell receptor engagement results in the 
immediate termination of the signaling process, with hierarchical thresholds for the induction 
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of T-cell proliferation and differentiation (Lanzavecchia and Sallusto, 2002). For the duration 
of TLR stimulation and the activation of DC, investigations did not always lead to consistent 
results. For TLR4 stimulation with LPS, upregulation of MHC and costimulatory molecules 
and CCR7 was induced very rapidly, while secretion of IL-12p70, IL-6, and IL-10 needed a 
sustained stimulation of more than 6 hours in one report (Macagno et al., 2006). Warger et 
al. showed that DC needed to be activated for 20 h with R848 or polyI:C, a synthetic TLR3 
ligand, to induce specific immune responses in mice (Warger et al., 2006). In our hands, 
short-term activation of DC with CpG was sufficient to induce complete maturation of DC. 
Extensive stimulation of DC could not enhance the production of the Th1 cytokines IL-12p70 
and IFN-α, which were secreted for only 8 hours after stimulation. Other studies support our 
results and show a potent activation of DC with short TLR stimulations: Camporeale et al. 
investigated the immune responses in mice elicited by DC activated for 8 h or 48 h with LPS 
and saw that 8h-DC were more effective in inducing antitumoral immunity in the B16 model 
of melanoma (Camporeale et al., 2003). When human DC were stimulated with a defined 
bacterial extract, which probably activates different TLRs simultaneously, the best induction 
of antigen-specific T cells was reached with DC activated for 6 h, while 20h-DC did not 
trigger CTL activity (Kaiser et al., 2003). Furthermore, DC activated for 48 h with LPS were 
shown to promote Th2 responses in contrast to 8h-DC, which induced Th1 responses 
(Langenkamp et al., 2000). 
 
DC can be exposed to a variety of stimuli including microbial products, inflammatory 
cytokines and signals provided by T cells. Several studies have documented how different 
stimuli can cooperate or synergize in the induction of particular aspects of DC maturation. In 
particular IL-12p70 secretion is boosted by a combination of different stimuli including IFN-γ, 
TLR agonists, and CD40L (Macagno et al., 2007). Still, IL-12 production is not only regulated 
by the combination of stimuli, but also by the order in which the stimuli are delivered over a 
defined period of time. IFN-γ enhances IL-12 secretion only if given before TLR agonists, and 
CD40 stimulation is maximally effective when given after a TLR stimulus (Schulz et al., 
2000). Unsurprisingly, this is the temporal order in which these stimuli can be encountered by 
the maturing DC under physiological conditions. The exposure of DC to different stimuli in an 
appropriate time frame represents an effective way to sustain signaling. However, there is a 
defined temporal window in which various signals can accumulate and integrate. This 
integration is optimal during cytokine gene expression, because DC become exhausted at 
later time points after stimulation, stop producing cytokines, and become refractory to further 
stimulation, as described above (Kalinski et al., 1999; Macagno et al., 2007). Thus, a short 
TLR stimulation may provide the necessary signals for DC maturation while offering a 
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temporal window for a potent CD40 activation by T cells once the injected DC have reached 
the draining lymph node.  
 
5.1.5 The need to generate multifunctional dendritic cells  
Apart from cytokine secretion and upregulation of the expression of MHC and costimulatory 
molecules, the upregulation of the chemokine receptor CCR7 is one functional consequence 
of DC maturation. Migration of DC towards gradients of the lymph node-directing chemokines 
CCL21 and CCL19 is key for enabling antigen-loaded DC to efficiently interact with T cells in 
draining lymph nodes (Forster et al., 1999). However, it has been demonstrated that 
chemokine receptor expression is not predictive of the migratory capacity of some DC types 
(Luft et al., 2002). Exposure of DC to PGE2 induces a migratory phenotype due to its 
participation in podosome dissolution and high-speed migration (van Helden et al., 2006). On 
the other hand, the presence of PGE2 during maturation of DC inhibits IL-12p70 production, 
thus impairing Th1-directed immunity (Kalinski et al., 2001; Luft et al., 2002). Together, these 
data suggest that highly migratory DC would be unable to produce IL-12, raising the question 
of the source of intranodally produced IL-12. Yet, DC used for clinical vaccination studies 
require both migratory and cytokine production capacities. Protocols that describe the 
generation of multipotent DC using TLR ligands or combinations of the proinflammatory 
cytokine cocktail with TLR ligands for DC maturation have not been examined with DC 
meeting clinical grade standard yet (Boullart et al., 2008; Dauer et al., 2008; Lehner et al., 
2007). Thus, there is currently no clinical grade maturation protocol available that yields DC 
combining migratory capacity and IL-12 production. 
 
In this study, short-term activation of DC by CpG enhanced the expression of CCR7 on DC 
as well as the migratory potential of DC to the lymph-node directing chemokine CCL21. In 
contrast, extensive activation of DC for 24 h through CD40 stimulation inhibited DC migration 
in another study (Watanabe et al., 2003). Thus, short-term activation of DC with a TLR9 
ligand has the advantage of inducing multifunctional DC capable of both lymph node 
migration and IL-12p70 production, that fit the desired physiological role to induce tumor 
specific IFN-γ-producing Th1 cells and CTL. 
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5.2 Pathways to IL-12 production: TLR7 versus TLR9 signaling 
The endosomal Toll-like receptors TLR7, 8, and 9, which all recognize specific patterns 
within nucleic acids, are thought to activate the same signaling pathway upon ligand binding. 
Strikingly, we observed a pronounced difference in IL-12p70 production after stimulation with 
TLR7 ligands compared to the TLR9 ligand CpG: Whereas CpG induced the secretion of 
large amounts of IL-12, the TLR7 ligand R848 did not trigger IL-12p70 production in mDC 
derived from FL-DC. We examined the underlying pathways to analyze this unexpected 
difference.  
 
5.2.1 IL-12 as a crucial regulator of immune responses 
The first response of an organism to pathogens is an inflammatory reaction, which 
constitutes the effector phase of innate resistance. Complete control of an infection however 
generally requires the induction of adaptive immunity. Yet, innate and adaptive immunity are 
not simply sequential and complementary mechanisms of resistance to pathogens, but 
regulate each other through cellular contacts and the secretion of soluble mediators, one of 
which is IL-12. The cytokine IL-12 is a heterodimer formed by a 35-kDa light chain known as 
p35 or IL-12A, and a 40-kDa heavy chain known as p40 or IL-12B. IL-12p40 associates not 
only with IL-12p35, but also with the molecule p19, thereby forming IL-23 (Oppmann et al., 
2000). IL-12p40 is produced in large excess over the p35 and p19 subunits and can also be 
secreted as homodimer, at least in the murine system (Heinzel et al., 1997). However, p40 
mRNA seems to be restricted to cells that produce the biologically active heterodimer, while 
mRNA encoding IL-12p35 is present in many cell types (D'Andrea et al., 1992). Transcription 
of both genes is induced after cell activation; the expression of p35 is considered to be rate-
limiting for heterodimer production. IL-12p35 gene transcription upon TLR engagement was 
found to depend on p65 and c-Rel members of the NF-κB family as well as on recruitment of 
Sp1. Furthermore, IL-12p35 gene expression is enhanced by IFN-γ via the recruitment of 
IRF-1 and ICSBP (interferon consensus sequence-binding protein, or IRF-8; Trinchieri, 
2003). The initial production of IL-12 occurs rapidly and has been shown to be independent 
of IFN-γ and CD40L-signals from T cells, although both stimuli enhance its production 
(Gazzinelli et al., 1994). 
 
The IL-12 receptor is expressed mainly by activated T cells and natural killer cells, but has 
also been detected on DC and B cell lines (Trinchieri, 2003). IL-12 has direct proliferative 
effects on pre-activated T cells and natural killer cells and induces their secretion of several 
cytokines, particularly IFN-γ, thus promoting Th1 and cell-mediated immunity. The importance 
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of IL-12 as an IFN-γ inducer lies not only in its high efficiency at low concentrations, but also 
in its synergy with many other activating stimuli, for example IL-2 and CD3 as well as CD28 
receptor signals (Trinchieri, 2003). The ability of IL-12 to induce and maintain antigen-
specific Th1 responses is essential to control infections with many microbial pathogens 
(Trinchieri, 1998). In addition, IL-12 has also been shown to have a marked anti-tumor effect 
in mouse tumor models by using effector mechanisms of both innate and adaptive immunity 
(Brunda et al., 1993). In the present study, DC activation with the TLR9 ligand CpG induced 
the secretion of high amounts of bioactive IL-12p70. However, when DC were activated with 
TLR7 ligands, mDC derived from FL-DC cultures did not produce significant amounts of 
IL-12. The promising data from pre-clinical models of anti-tumor immunotherapy indicates 
that IL-12 might be a powerful therapeutic agent against cancer, although excessive toxicity 
and a modest response in clinical trials have dampened the enthusiasm (Colombo and 
Trinchieri, 2002). Nevertheless, the ability of DC-based tumor vaccines to elicit IL-12 
production may to some extent determine their success. As TLR7 ligands are promising 
alternatives to CpG in clinical studies, the induction of IL-12 production upon TLR7 
stimulation needs to be examined in closer detail. Comparably to the divergence between 
murine Flt3L-derived mDC and GM-CSF plus IL-4 – generated mDC, IL-12p70 secretion may 
be differentially regulated in different human DC subpopulations. This should also be 
analyzed in order to establish successful DC vaccination protocols. 
 
5.2.2 IL-10 – an anti-inflammatory cytokine exerting regulatory feedback 
Although IL-12 is essential to elicit potent cellular immune responses, excessive 
inflammatory cytokine production results in tissue damage and toxicity that is harmful to the 
host. Thus, strong inducers of inflammatory cytokines also activate homeostatic mechanisms 
that serve to limit cell activation, cytokine production, and tissue damage (Hu et al., 2006). 
The induction of IL-10 is one key regulatory feedback loop that limits inflammatory cytokine 
production by inhibiting multiple effector functions of DC and macrophages. The importance 
of the regulatory role of IL-10 is shown by the uncontrolled lethal inflammatory response to 
various pathogens in IL-10-deficient mice (Gazzinelli et al., 1996). 
 
IL-10 was first described as cytokine synthesis inhibitory factor (CSIF) produced by Th2 cells 
that inhibits activation and cytokine production of Th1 cells. The functional IL-10 receptor 
complex is a tetramer consisting of two α-chains and two β-chains. Activation of the IL-10 
receptor leads to the activation of the JAK-STAT signaling pathway and the transcription 
factors STAT1, STAT3 and STAT5 (Wehinger et al., 1996). SOCS3 (suppressor of cytokine 
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signaling 3) is one of the IL-10-responsive genes inhibiting the expression of various 
inflammatory genes. The ability of IL-10 to inhibit cytokine production by T cells and natural 
killer cells was found to be indirect via inhibition of antigen-presenting cells, where it 
suppresses the production of a number of pro-inflammatory cytokines including IL-12, TNF, 
IL-1β, and IL-6, at the same time as inhibiting the expression of MHC class II and 
costimulatory molecules. In monocytes and macrophages, IL-10 also inhibits the synthesis of 
superoxide anions and NO (Moore et al., 2001). Considering that IL-10 as well as IL-12 play 
pivotal roles in immune regulation, the elucidation of the molecular mechanism underlying 
their expression would shed new light on therapeutic approaches toward cancer on the one 
hand, but also in the context of autoimmune diseases on the other. In this study, we 
identified IL-10 as a key inhibitor of IL-12 production in FL-mDC after TLR7 stimulation, as 
IL-10-deficient cells secreted high amounts of IL-12 upon R848 stimulation. Nevertheless, 
other mechanisms are obviously enforcing the suppression of IL-12, as the IL-10 levels after 
CpG stimulation are at least as high as after R848 stimulation but do not inhibit CpG-induced 
IL-12 production. 
 
5.2.3 IFN-β: the pivotal molecule? 
In murine as well as human DC, IFN-γ priming is usually required in order to observe 
significant IL-12p70 secretion in response to TLR stimulation (Hayes et al., 1995). As IFN-γ 
and type I IFN receptors activate a common signaling pathway, the role of endogenous type I 
IFNs in IL-12p70 production has been examined previously. An autocrine feedback loop of 
type I IFNs, especially IFN-β, which induces STAT1 phosphorylation was found to be 
required for the secretion of bioactive IL-12 in myeloid DC after TLR7/8 stimulation (Gautier 
et al., 2005), while another group reported the inhibition of IL-12p70 production by IFN-β in 
DC infected with respiratory syncytial virus (Rudd et al., 2007). Data from our microarray 
experiment did indeed show an upregulation of IFN-β expression after CpG but not after 
R848 stimulation. Expression of IFN-α was also upregulated slightly but significantly after 
TLR9 activation only. In addition, FL-mDC from IRF3/7 knock-out mice deficient in type I IFN 
production showed markedly reduced levels of IL-12p70 secretion after CpG stimulation, 
indicating the importance of type I IFN priming for IL-12p70 production in our experiments. 
Recent publications have identified IL-27, another member of the IL-12 family of cytokines, 
as yet another modulator of cytokine responses after TLR stimulation: It was shown to be 
specifically induced by IFN-β and to enhance STAT1-dependent inflammatory gene 
transcription at the same time as altering IL-10 signaling (Kalliolias and Ivashkiv, 2008; 
Remoli et al., 2007). Interestingly, expression of IL-27 subunits was also increased more 
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potently after CpG than after R848 stimulation, further supporting a key role of this pathway 
in the IL-12 regulation in our settings. Further experiments are necessary to specify the 
influence of IFN-β, IL-27, and STAT1 phosphorylation in the induction of IL-12p35 expression 
upon TLR9 but not TLR7 stimulation. 
 
 
5.3 Conclusion and perspectives 
DC play a pivotal role in the initiation, programming, and regulation of tumor-specific immune 
responses. DC vaccines using the immunostimulatory power of activated DC have emerged 
as one of the most promising strategies for the immunotherapy of cancer (Melief, 2008; 
Steinman and Banchereau, 2007). In the present study, we show that a short-term activation 
of DC by the TLR 9 ligand CpG for as little as 4 hours irreversibly programs DC to produce 
Th1-associated cytokines and is highly effective in inducing an antitumoral T-cell response. 
Short-term activated DC also acquired migratory function towards a CCR7 ligand and were 
able to overcome the immune suppression mediated by Treg cells. Thus, short-term activation 
of DC by CpG as a novel strategy of DC maturation generates fully functional DC for tumor 
immunotherapy. These results may help to develop new concepts for DC activation in DC-
based tumor vaccines. 
 
Many of the molecular changes that allow a tumor to grow also create an 
immunosuppressive milieu that counteracts tumor rejection by the immune system and may 
thus restrict the effects of DC-based immunotherapies. Until now, DC-based vaccines have 
mostly been used to treat late-stage tumors in patients, where the presence of large tumor 
masses impedes the access of tumor-specific lymphocytes to the tumor. Hence, 
immunotherapeutic approaches may confer a more pronounced benefit when applied earlier 
during the course of disease. Combining DC-based therapies with other strategies such as 
chemotherapy may also prove an effective strategy: Interestingly, the simultaneous 
administration of chemotherapy does not reduce the effects of immunotherapy despite the 
immunosuppression often associated with chemotherapy (Bourquin et al., 2006). It may even 
enhance antitumoral effects by “resetting” the relationship between the tumor and the 
immune system: chemotherapy can, by simply reducing the tumor mass, reduce its 
immunosuppressive properties. In addition, the chemotherapy-induced lymphopenia reduces 
the number of regulatory cells and may promote the proliferation of immune effectors that are 
particularly active in the anticancer response (Zitvogel et al., 2008). Thus, a combination of 
chemotherapy and optimized DC-based immunotherapies might help to further improve the 
clinical outcome of tumor therapy.  
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In the second part of this study, the deficient IL-12p70 production upon Toll-like receptor 7 
stimulation in Flt3L-derived mDC was examined. By analyzing inhibitors of signal 
transduction, knock-out mice, and genome-wide expression levels of R848- versus CpG-
stimulated cells, p38 MAPK, IL-10, and IFN-β were identified as regulators of IL-12. Further 
experiments will elucidate the respective importance of these molecules and identify putative 
additional regulators of IL-12 expression.  
 
IL-12 production in DC is clearly regulated by several different pathways. The phospho-
inositide 3-kinase (PI3K) pathway has recently been shown to play an additional role in IL-12 
and IL-10 expression: PI3K negatively regulates IL-12 production while inducing IL-10 
transcription in DC stimulated with TLR ligands. Certain signaling molecules involved in the 
PI3K pathway, namely Akt, mTOR (mammalian target of rapamycin), and GSK3 (glycogen 
synthase kinase 3), have been shown to play a role in this process (Fukao et al., 2002; 
Ohtani et al., 2008). However, these regulatory pathways have so far only been examined in 
human monocytes and/or murine GM-CSF DC stimulated with LPS. The influence of these 
pathways on the signaling of other TLRs and in other cell types deserve further analysis and 
might help to elucidate the complex regulation of IL-12 production.  
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7.1 Abbreviations 
A 
Ab    Antibody 
ANOVA   Analysis of variance 
AP-1    Activated protein 1 
APC    Allophycocyanin 
B 
BrdU    5’-Bromo-2’-deoxyuridine 
BSA    Bovine serum albumin 
C 
CCL    Chemokine (C-C motif) ligand 
CCR    C-C chemokine receptor 
CD    Cluster of differentiation 
cDNA    Complementary DNA 
cRNA    Complementary RNA 
CFSE    Carboxyfluorescein succinimidyl ester 
CpG    Oligonucleotide with cytosine-(phosphate)-guanine motifs 
CTL    Cytotoxic T lymphocyte 
D 
d    Day 
DC    Dendritic cell 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
E 
EDTA    Ethylene diamine tetraacetic acid 
ELISA    Enzyme-linked immunosorbent assay 
F 
FACS    Fluorescence-activated cell sorting 
FCS    Fetal calf serum 
FITC    Fluorescein isothiocyanate 
FL-DC    Flt3L-derived dendritic cells 
Flt3L    Fms-like tyrosine kinase 3 ligand 
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FSC    Forward scatter 
G 
GM-CSF   Granulocyte-macrophage colony stimulating factor 
GM-DC   Dendritic cells differentiated with GM-CSF and IL-4 
GSK3    Glycogen synthase kinase 3 
H 
HBSS    Hank's balanced salt solution 
HRP    Horseradish peroxidase 
I 
ICSBP    Interferon consensus sequence-binding protein 
IDO    Indoleamine 2,3-dioxygenase 
IFN    Interferon 
Ig    Immunoglobulin 
IκB    Inhibitor of κB 
IKK    Inhibitor of κB kinase 
IL    Interleukin 
IP-10    Interferon-induced protein 10 
IRAK1/4   IL-1R-associated kinase 1/4 
IRF    Interferon-regulatory factor 
J 
JAK    Janus kinase 
L 
LPS    Lipopolysaccharide 
M 
MACS    Magnetic cell separation or magnetic-activated cell sorting 
Mal    MyD88 adaptor-like  
MAPK    Mitogen-activated protein kinase 
mDC    Myeloid dendritic cell 
MHC    Major histocompatibility complex 
MyD88   Myeloid differentiation primary response gene 88 
mRNA    Messenger ribonucleic acid 
mTOR    Mammalian target of rapamycin 
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N 
NF-κB    Nuclear factor-κB 
NK cells   Natural killer cells 
ns    Not significant 
O 
OPD    O-phenylenediamine dihydorochloride 
OT-I    Transgenic mice with ovalbumin-specific CD8+ T cells 
OT-II    Transgenic mice with ovalbumin-specific CD4+ T cells 
OVA    Chicken egg ovalbumin 
P 
PBS    Phosphate-buffered saline 
pDC    Plasmacytoid dendritic cell 
PE    R-phycoerythrin 
PerCP    Peridinin chlorophyll protein 
PI3K    Phosphoinositide 3-kinase 
PFA    Paraformaldehyde 
PGE2    Prostaglandin E2 
pre-DC   Precursor of DC 
R 
RBC    Red blood cells (erythrocytes) 
RNA    Ribonucleic acid 
RT    Room temperature 
S 
SOCS3   Suppressor of cytokine signaling 3 
SSC    Side scatter 
STAT    Signal transducer and activator of transcription 
T 
TAB1/2   TAK1-binding protein 1/2 
TAK1    TGF-β-activated protein kinase 1 
TBK1    Traf family member-associated NF-κB activator binding protein 
TCR    T-cell receptor 
Th    T helper 
TIR    Toll/IL-1 receptor 
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TLR    Toll-like receptor 
TMB    Tetramethyl benzidine 
TNF    Tumor necrosis factor 
TRAF6   TNF receptor-associated factor 6 
TRAM    TRIF-related adaptor molecule 
TRIF    TIR-related adaptor protein inducing interferon 
Treg cells   Regulatory T cells 
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7.2 Publications 
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2. Bourquin C, Anz D, Zwiorek K, Lanz AL, Fuchs S, Weigel S, Wurzenberger C, von der 
Borch P, Golic M, Moder S, Winter G, Coester C, Endres S.  
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Cancer Immunology, Immunotherapy 2008 Oct 25; Epub ahead of print (JIF: 3.7) 
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6. Wurzenberger C, Weber P, Schlee M, Bscheider M, Schreiber S, Anz D, Vollmar AM, 
Endres S, Bourquin C.  
IL-12 production in murine dendritic cells is differentially regulated after TLR7 versus 
TLR9 stimulation. 
In preparation 2008 
 
7.2.2 Oral presentations 
1. The duration of dendritic cell activation with CpG oligonucleotides is critical for the 
outcome of immunotherapy in a mouse model of colon cancer 
9th International Conference on Dendritic Cells, Edinburgh, UK, 2006 
 
2. Immunotherapy of tumors 
1st Annual Retreat, Graduiertenkolleg 1202, Frauenchiemsee, Germany, 2006 
 
3. Kinetics of dendritic cell activation in tumor therapy 
ICE School (Immunology Course Engadina), Bos-Cha, Switzerland, 2007 
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2nd Annual Retreat, Graduiertenkolleg 1202, Tutzing, Germany, 2007 
 
5. DC vaccination for tumor therapy 
Junior Science Faculty, SFB-Transregio 36, Tutzing, Germany, 2007 
7.2.3 Poster presentations 
1. Bourquin C, Wurzenberger C, Schreiber S, Hartmann G, Endres S.  
Flt3L-generated dendritic cells are superior to GM-CSF- plus IL-4 – derived dendritic 
cells for immunotherapy with CpG oligonucleotides in a mouse model of colon cancer. 
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3. Wurzenberger C, Heidegger S, Schreiber S, Weigel S, Koelzer V, Endres S, Bourquin 
C. Kinetics of DC activation by CpG oligonucleotides for the induction of CD8 T cell 
responses. 
5th International Meeting on Dendritic Cell Vaccination and other strategies to tip the 
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